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Abbreviations: 
 
AML  Acute Myeloid Leukemia 
ALL  Acute Lymphoid Leukemia 
APL  Acute Promyelocytic Leukemia 
β-ME  β-Mercaptoethanol 
BR-LZ Basic Region-Leucine Zipper 
CLP  Common Lymphoid Progenitor  
CHAPS  3-[(3-Cholamidopropyl) Dimethylammonio]-1-Propanesulfonate 
C/EBP  CCAAT Enhancer Binding Protein 
CML  Chronic Myeloid Leukemia 
CK   Complex Karyotype 
CHX  Cycloheximide 
2 DE  2 Dimensional Gel Electrophoresis  
DTE  Dithioerythritol  
DTT  Dithiothreitol 
DHB  2,5-Dihydroxy-Benzoicacid 
DMEM Dulbecco´s Modified Eagle Medium 
DMSO Dimethylsulfoxide 
EDTA Ethylenediamine Tetra-Acetic Acid 
EGTA Ethylene Glycol bis (2-aminoethyl ether)-N,N,N'N'-Tetra Acetic 
Acid 
FAB  French American British Classification 
GMPs Granulocyte/Macrophage Progenitors  
GST   Glutathione-S-Transferase  
GCSF   Granulocyte Colony Stimulating Factor 
GCSFr  Granulocyte Colony Stimulating Factor Receptor  
HSC   Haematopoietic Stem Cell 
HA   Hemeagglutinin 
IB                Immunoblot 
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IEF  Isoelectric Focussing       
IPTG  Isopropyl-beta-D-Thiogalactopyranoside 
Ip      Immunoprecipitation  
Ivt                In-vitro Translated 
JNK   c-Jun NH2 -Terminal Kinase 
JNK*           Kinase dead c-Jun NH2-Terminal Kinase (mutant JNK)  
MALDI Matrix Assisted Laser Desorption Ionisation- Time of Flight  
MEPs  Megakaryocyte/Erythroid Progenitors  
MAPK  Mitogen Activated Protein Kinase 
µl  Microlitres 
µg  Micrograms 
µCi  Micro Curie 
MS  Mass Spectrometry 
NP40  Nonidet P-40  
ng  Nanogram 
NK  Normal Karyotype 
nBM  Normal Bone Marrow 
PMF   Peptide Mass Fingerprinting 
pI  Isoelectric Point 
RIPA  Radioimmunoprecipitation 
RT   Room Temperature 
Rpm  Revolutions per Minute 
SDS   Sodium Dodecyl Sulphate 
TE  Transactivation Elements  
TAD  Transactivation Domain 
TBE  Tris-Borate EDTA 
TOF  Time of Flight 
UVB  Ultra Violet Radiation B 
WHO  World Health Organization 
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1. Introduction: 
1.1 Haematopoiesis: 
 
The haematopoietic system is a paradigm for the development of different 
specialized cell types from multipotent progenitors. Pluripotential haemato- 
poietic stem cells — an extremely rare population (<0.1%) of nucleated bone-
marrow cells — undergo a decision to either self-renew or remain pluripotent or 
to differentiate into immature but committed progenitor cells. These progenitor 
cells differentiate into either lymphoid, erythroid, megakaryocytic or myeloid 
precursors in the bone marrow (Tenen, 2003).  
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Fig 1. Role of transcription factors in haematopoietic development: Long-term and short-
term haematopoietic stem cells (HSCs) provide long-term (more than 3 months) and short-
term reconstitution in lethally irradiated mice. The common lymphoid progenitor (CLP) gives 
rise to T and B cells, whereas the common myeloid progenitor (CMP) gives rise to 
granulocyte/macrophage progenitors (GMPs) and megakaryocyte/erythroid progenitors 
(MEPs). Upregulation of the transcription factor PU.1 is essential for the transition from HSC 
to CLP, whereas downregulation of PU.1 is required for the differentiation of CMP to MEP. 
CCAAT/enhancer binding protein- (C/EBP)α upregulation initiates the transition from CMP 
to GMP. One hypothesis is that the 'default' pathway involves differentiation of GMPs to 
monocytes and macrophages, which depends on PU.1 activity. In this model, C/EBP subverts 
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this default monocytic pathway and promotes differentiation into granulocytes — perhaps 
through inhibition of PU.1 function. On contrary, C/EBPα inhibition by AML1/ETO and 
BCR-ABL has been implicated in patients with acute myeloid leukemia. Adapted from Nature 
reviews, Tenen DG,(Tenen, 2003) 
 
The past two decades have witnessed significant advances in our understanding 
of the cellular physiology and molecular regulation of haematopoiesis and 
myelopoiesis. Several recent reviews and studies focus on the importance of 
lineage specific transcription factors for the specification of the myeloid, 
lymphoid and erythroid lineages (Friedman, 2002; Orkin, 1996; Sieweke and 
Graf, 1998; Tenen, 2000). 
The central role of transcription factors in these processes has been 
highlighted by gene inactivation studies, promoter analysis, and ectopic 
expression of lineage restricted factors (Sieweke and Graf, 1998). Figure 1, 
depicts a schematic representation of transcription factors required at different 
lineage specification while haematopoiesis. 
 
1.2 Transcription factors involved in normal myelopoiesis: 
 
Rather than being controlled by single master regulators, lineage specific gene 
expression appears to depend on the combination of factors in overlapping 
expression domains (Ness and Engel, 1994). Important transcription factors 
involved in normal haematopoiesis are listed in Table 1. 
Table 1: Transcription factors involved in normal haematopoiesis: 
Factor Expression Gene-Target products Comments 
AML1 HSCs and most others M-CSF receptor; T-cell 
receptor enhancer 
Knockouts lack all 
definitive haematopoiesis; 
conditional knockouts 
develop moderate 
thrombocytes 
GATA1 HSCs,CMPs,MEPs not 
in GMPs or Lymphoid 
Erythropoietin receptor and 
many others 
Knockouts lack all 
definitive erythropoiesis 
PU.1 All progenitors; 
downregulated in 
erythroid and T-cells 
Receptors for GM-CSF,G-
CSF and M-CSF, and many 
others 
Knockout leads to 
complete loss of 
macrophages and B cells, 
Delayed development of T 
cells and granulocytes; the 
block at the HSC to CLP 
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transition and at CMP 
stage 
C/EBPα HSCs, CMPs, GMPs 
not in MEPs or 
Myeloid cells 
Receptors for G-CSF,IL-6, 
E2F, c-Myc; and primary 
granule proteins 
Knockout results in 
complete loss of 
granulocytic maturation, 
block at the CMP to GMP 
stage, and can induce 
granulocytic and block 
monocytic differentiation 
of multipotential cell lines. 
C/EBPβ Most G-CSF and others Knockout shows not 
required for myeloid 
development but has role 
in macrophage activation, 
knock in to C/EBPα locus 
rescues granulopoiesis 
C/EBPε Granulocytic and 
lymphoid cells 
Secondary granule proteins Knockout blocks terminal 
granulocyte maturation 
and function. 
Adapted from Nature Reviews Cancer (Tenen, 2003). 
 
1.3 Acute Myeloid Leukemia: 
Acute myeloid leukemia (AML) is a malignant disease of the haematopoietic 
system in which cells of one of the myeloid lineages (erythrocytes, 
megakaryocytes, granulocytes, monocytes/macrophages) accumulate in an 
undifferentiated state due to accumulation of mutations that prevent their normal 
differentiation and allow undifferentiated cells to survive (Bob Löwenberg, 
1999; Nerlov, 2004; Nerlov and Graf, 1998). The fundamental biological 
features of the malignant cells in AML are their ability to proliferate 
continuously with an aberrant or arrested differentiation (Scandura et al., 2002). 
The French American British classification, introduced approximately 25 years 
ago (Bennett et al., 1976; Harris et al., 1999) remains the foundation on which 
the morphologic diagnosis of AML and ALL is based (Table 2). However, the 
new World Health Organization (WHO) classification takes into account 
cytogenetics, molecular genetics, morphologic and immunophenoytic findings 
(Harris et al., 1999; Harris et al., 2000a; Harris et al., 2000b; Harris et al., 
2000c). 
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Table 2: The French American British classification of AML: 
FAB Subtype Description Comments 
M0 Undifferentiated Myeloperoxidase negative, Myeloid 
markers positive;  
M1 Myeloblastic without maturation Some evidence of granulocytic 
differentiation 
M2 Myeloblastic with maturation Maturation at or beyond the 
promyelocytic stage of differentiation; 
can be divided into those with t(8;21) 
AML1-ETO fusion and those without  
M3 Promyelocytic APL; most cases have t(15;17) PML-
RARα or another translocation 
involving RARα 
M4 Myelomonocytic  
M4e0 Myelomonocytic with bone 
marrow eosinophilia 
Characterized by inversion of 
chromosome 16 involving CBFb, which 
normally forms a heterodimer with 
AML1 
M5 Monocytic  
M6 Erythroleukemia  
M7 Megakaryoblastic GATA mutations in those associated 
with Down´s syndrome. 
Adapted from Nature Reviews Cancer (Harris et al., 1999; Tenen, 2003) 
 
Much is known about the signals that control cell survival and proliferation, 
whereas signals required for differentiation are not well defined (Tenen, 2003). 
In the past few years, a number of studies have pointed to the dominant role of 
lineage specific transcription factors in normal hematopoietic differentiation 
(Nerlov and Graf, 1998; Rangatia et al., 2002; Zhang et al., 1997). These studies 
predicted that the function of these transcription factor pathways would be 
disrupted in AML.  Recent studies have confirmed this hypothesis, showing that 
a number of cases of AML are not associated with a consistent translocation, but 
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with small mutations in the coding regions of these lineage specific transcription 
factors or their inhibition by other inhibitory proteins by direct protein-protein 
interactions (Nerlov, 2004; Nerlov, 2000; Pabst et al., 2001a; Pabst et al., 2001b; 
Vangala et al., 2003). In addition, in many of those cases the resulting 
translocation product disrupts the expression and/or function of lineage specific 
factors (Pabst et al., 2001a; Perrotti et al., 2002). In fact, the most common 
genetic mechanism that is associated with AML and ALL, is the aberrant 
expression of transcription factors or the production of an abnormal hybrid 
transcription factor (Jing, 2004; Pabst et al., 2001a; Perrotti et al., 2002). 
Hematopoietic transcription factors often associated with AML are listed in 
table 3.   
Table 3: Transcription Factors associated with AML: 
Factor Subtype Mutation 
AML1 FAB M0 Often biallelic mutations 
AML1 FAB M2 t(8;21) AML1-ETO and 
AML1/Evi1 
GATA1 FAB M7 associated with 
Down´s syndrome 
Amino terminal mutations 
similar to those seen with 
C/EBPα 
PU.1 M0,M4,M5,M6 Not associated with common 
chromosomal translocations; 
mostly M0 and M4 without 
inv 16 
C/EBPα M1,M2 few M4 Mutation not associated with 
t(8;21); amino-terminal 
dominant negative 
C/EBPα M2 with t(8;21) No mutation; downregulation 
at RNA level 
C/EBPα CML myeloid-blast crisis No mutation; downregulation 
at protein level 
C/EBPα APL No downregulation; loss of 
DNA binding in cell lines; 
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C/EBPβ and C/EBPε 
mediate ATRA response in 
AML. 
CBFβ M4e Inversion of chromosome 16 
involving CBFβ 
FLT3  Involved in translocation 
with ITD and is often 
mutated 
Adapted from Nature Reviews, Cancer (Tenen, 2003). 
 
1.4 Role of C/EBPα in myelopoiesis: 
The CCAAT enhancer binding protein alpha (C/EBPα) is a key transcription 
factor involved in granulocytic differentiation and in general myelopoiesis 
(McKnight, 1991; Radomska et al., 1998; Zhang et al., 1997). C/EBPα belongs 
to the C/EBP family of proteins first identified from rat liver nuclear proteins 
(Landschulz et al., 1988; Landschulz et al., 1989). CCAAT enhancer binding 
proteins encompass a family of transcription factors with structural as well as 
functional homologies. C/EBP proteins consist of an activation domain at the N-
terminal, a DNA binding basic region (BR) and a Leucine-rich  dimerization 
domain aptly termed the “leucine zipper” (LZ) at the carboxyl terminus 
(Landschulz et al., 1989).  
In the past few years, the study of lineage specific transcription factors 
such as C/EBPs has greatly increased our knowledge of mechanisms underlying 
the regulation of myelopoiesis and haematopoiesis in general (Friedman, 2002; 
Nerlov, 2004; Pabst et al., 2001a; Pabst et al., 2001b; Sieweke and Graf, 1998; 
Tenen, 2000; Tenen, 2001; Tenen, 2003). The genes of six C/EBP members 
have been cloned to date from several species and have been given a systematic 
nomenclature in which members are designated as C/EBP followed by a Greek 
letter indicating the chronological order of their discovery (C/EBPα-ζ) (Akira et 
al., 1990; Cao et al., 1991; Chang et al., 1990; Descombes et al., 1990; Ramji 
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and Foka, 2002; Roman et al., 1990; Ron and Habener, 1992; Williams et al., 
1991). A brief description of C/EBP proteins involved in haematopoiesis, 
myelopoiesis and their association with AML is given in table 1and 3. 
 C/EBPs are key regulators of growth and differentiation of many tissues 
and cell types in-vivo; The transcription factor C/EBPα in particular has been 
shown to play a pivotal role during differentiation in various cell types, including 
adipocytes, hepatocytes, keratinocytes, lung, prostrate and ovary cells (Cao et al., 
1991; Flodby et al., 1996; Lin and Lane, 1994; Radomska et al., 1998; Umek et al., 
1991; Zhang et al., 1997). Within hematopoiesis, full length C/EBPα, C/EBPβ 
and C/EBPδ are expressed in the monocyte, granulocyte and eosinophil lineage 
(Friedman, 2002). However, C/EBPα is the predominant isoform expressed in 
early myeloid cells. Figure 2, depicts the temporal expression of various C/EBP 
proteins during granulopoiesis.  
 
Fig 2. Expression profile of C/EBP proteins during Granulopoiesis: Granulopoiesis is the 
formation of mature neutrophil granulocytes from immature myeloblasts through a 
differentiation process that involves the cessation of cellular proliferation concomitant with 
the sequential synthesis of a number of enzymes and structural proteins that make up the 
different types of granules contained in the granulocyte. The figure shows their relative 
contribution to the granulocytic compartment (as percent of total nucleated bone-marrow cells 
(Duprez et al., 2003), as well as the expression pattern of the C/EBPα, C/EBPβ and 
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C/EBPε (Bjerregaard et al., 2003), (Weinstein, 1995) proteins during the process of 
granulocyte differentiation, Adapted from Nature Reviews, Cancer. (Nerlov, 2004). 
 
 Previous studies have demonstrated that the expression of C/EBPα 
correlates with the commitment of multipotential precursors to the myeloid 
lineage, and is specifically upregulated during neutrophil differentiation 
(Radomska et al., 1998; Scott et al., 1992). Moreover, conditional expression of 
C/EBPα  is sufficient to induce neutrophil differentiation (Radomska et al., 1998; 
Wang et al., 1999) and can block the monocytic differentiation program in 
bipotential myeloid precursors (Radomska et al., 1998). In addition, studies with 
targeted disruption of the C/EBPα gene demonstrate a selective block in the 
differentiation of neutrophils while all the other blood cell types are present in 
normal proportions (Zhang et al., 1997). C/EBPα knockout mice do not express 
granulocyte colony-stimulating factor receptor (G-CSFr) which is a critical target 
gene of C/EBPα. As a result, multipotential myeloid progenitors from the mutant 
foetal liver are unable to respond to granulocyte colony-stimulating factor (G-
CSF) signalling, although they are capable of forming granulocyte-macrophage 
and macrophage colonies in methylcellulose in response to other growth factors 
(Zhang et al., 1997). In fact, C/EBPα is not only essential for granulocyte 
development but, in addition, is a regulator of haematopoietic stem cell activity 
(Zhang et al., 2004). 
 Few critical target genes of C/EBPα have been identified and studied 
thoroughly. The C/EBPα protein activates the CD14 promoter and mediates TGF-
β signalling during monocyte development. CD14 is a monocyte/macrophage 
differentiation marker which is strongly upregulated during monocytic 
differentiation. Myelomonoblastic U937 cells differentiate into monocytic cells 
upon treatment with vitamin D3 and TGF-β which is accompanied by a specific 
increase in the DNA binding and the expression of C/EBPα and C/EBPβ (Zhang 
et al., 1997). c-Myc is another target gene of C/EBPα, regulated negatively in 
granulopoiesis as shown by Johansen et. al. (Johansen et al., 2001). They 
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mapped an E2F binding site in the c-Myc promoter as the cis-acting element 
critical for C/EBPα negative regulation; they show that stable expression of c-
Myc from an exogenous promoter not responsive to C/EBPα-mediated down-
regulation, forces myeloblasts to remain in an undifferentiated state.  Therefore, 
C/EBPα negative regulation of c-Myc is critical for allowing early myeloid 
precursors to enter a differentiation pathway. This was the first report to 
demonstrate that C/EBPα directly affects the level of c-Myc expression and; the 
decision of myeloid blasts to enter into the granulocytic differentiation pathway 
(Johansen et al., 2001). Moreover, C/EBPα directly activates transcription from 
lineage-specific promoters.  
 Recent studies have emphasized that the interaction of transcription 
factors with other nuclear proteins plays an important role in a combinatorial 
fashion in stem cell development, lineage commitment and differentiation in the 
haematopoietic system (Behre et al., 2002a; Behre et al., 1999b; Nerlov, 2000; 
Sieweke and Graf, 1998; Zhang et al., 2000). Indeed C/EBPα also functions via 
protein-protein interaction; Janki et al. have shown that downregulation of c-Jun 
by C/EBPα is critical for granulocytic differentiation. Their data demonstrate 
that C/EBPα interacts directly with c-Jun in the leucine zipper domain and 
thereby attenuates its DNA binding, which in turn inhibits c-Jun expression and 
its  transactivation capacity (Rangatia et al., 2002). Direct physical interaction of 
C/EBPα with PU.1 in its β3, β4 domains has been reported to be essential for 
PU.1 inactivation by C/EBPα to drive granulocytic differentiation (Reddy et al., 
2002). Besides, the importance of protein-protein interaction is also evidenced 
by the fact that C/EBPα interacts with different protein partners in young and 
old mice liver to execute its function (Polina Iakova, 2003; Timchenko, 2003). 
Direct contact with the basal transcription apparatus (TBP/TFIIB) (Nerlov and 
Ziff, 1995), interaction with histone acetyltransferases (CBP/p300) (Schwartz et 
al., 2003) and recruitment of chromatin-remodelling complexes (SWI/SNF) 
(Pedersen et al., 2001) have all been implicated in the activation of lineage-
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specific genes by C/EBPα. An important function of the lineage specific factor 
C/EBPα is the inhibition of proliferation (Harris et al., 2001; Wang et al., 2001). 
Cells that are terminally differentiated and do not undergo proliferation have an 
inhibition in their cell cycle apparatus. This is particularly true for C/EBPα 
which works through multiple mechanisms to activate p21, inhibit E2F, and 
inhibit CDK function (Harris et al., 2001; Porse et al., 2001; Wang et al., 2001; 
Wang et al., 2003). In fact, several studies indicate that inhibition of E2F might 
be the most critical target of C/EBPα. Figure 3, depicts the characterized 
functional domains and interacting proteins of wild type C/EBPα (p42) and the 
N-terminal dominant negative mutant form C/EBPα(p30) which is often 
upregulated in patients with acute myeloid leukemia (AML). 
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Fig 3. Distribution of C/EBPα domains and its known interacting proteins: The location 
of characterized functional domains within the CCAAT/enhancer-binding protein-α 
(C/EBPα) protein. The basic region leucine zipper (BR-LZ) domain has been shown to 
mediate interaction with other transcription factors involved in lineage-specific gene 
regulation (such as GATA1, PU.1, ETS1 and RUNX1) and growth control (such as c-JUN 
and E2F). The three transactivation elements; TE-I, TE-II and TE-III mediate interactions 
with the transcriptional machinery (TBP/TFIIB; CBP/p300; SWI/SNF). In addition, p30 has 
been proposed to interact with the cyclin-dependent kinase inhibitor WAF1 (also known as 
p21), and with the cyclin-dependent kinases CDK2 and CDK4. Finally, glycogen synthase 
kinase 3 (GSK3) and protein kinase C (PKC) have been reported to phosphorylate distinct 
sites (Charles W. Mahoney, 1992; Ross et al., 1999) 
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1.5 C/EBPα inactivation in acute myeloid leukemia: 
Acute myeloid leukemia (AML) is characterized by an increase in the number of 
myeloid cells in the bone marrow and an arrest in their maturation, frequently 
resulting in hematopoietic insufficiency with or without leukocytosis (Bob 
Löwenberg, 1999). On the basis of morphology and cytogenetics AML has been 
classified in different FAB subtypes (Bennett et al., 1976). Although precise 
aetiology of AML is not clearly known, various somatic genetic alterations in 
hematopoietic stem or progenitor cells are known to cause malignant 
transformation which leads to leukemia (Gilliland et al., 2004). Recent studies 
have confirmed that function of lineage specific transcription factors is disrupted 
in AML which is either due to mutation or their functional inactivation by other 
inhibitory proteins (Nerlov, 2004). In addition, in many AML cases that are 
associated with a chromosome translocation, the resulting translocation product 
disrupts the expression and/or function of lineage specific transcription factors 
(Tenen, 2003).  
We recently reported that dominant-negative mutations of C/EBPα are 
found in patients with acute myeloid leukemia of subtypes M1 and M2.  
Heterozygous mutations were found in the CEBPα gene in ten patients with 
acute myeloid leukemia (AML); five mutations in the amino terminus truncated 
the full-length protein, but did not affect a 30-kD protein initiated further 
downstream. The mutant proteins block wild-type C/EBPα DNA binding and 
transactivation of granulocyte target genes in a dominant-negative manner 
resulting in the impairment of differentiation (figure 3). Since then several 
reports of C/EBPα gene mutation have been observed and reported (Frohling and 
Dohner, 2004; Frohling et al., 2004; Perrotti et al., 2004). In fact, C/EBPα is 
mutated in approximately 9% of AML — most prominently in the M2 subtype, 
where C/EBPα mutations are observed in up to 20% of patients but also in other 
granulocyte-lineage leukaemias (Nerlov, 2004). Furthermore, Fröhling et al. 
have demonstrated that mutation of C/EBPα predicts a favourable prognosis in 
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AML with normal cytogenetics. Recently C/EBPα mutation has been implicated 
in inherited AML (Smith et al., 2004).  
 Besides mutations in CEBPα gene, C/EBPα protein function is also 
disrupted in AML by negative  protein-protein interactions (Rangatia et al., 2003; 
Westendorf et al., 1998). AML1-ETO associates with C/EBPα, inhibits C/EBPα 
dependent transcription of the myeloid specific rat defensin NP-3 promoter, and 
blocks granulocytic differentiation (Westendorf et al., 1998). Moreover, we have 
also shown that the leukemic fusion protein AML1-ETO, found in patients with 
acute myeloid leukemia with translocation t(8;21), downregulates C/EBPα 
expression and inhibits its function in primary AML patients (Pabst et al., 2001a). 
 The PML-RARα fusion protein, which is the signature of acute 
promyelocytic leukemia (APL) results from the translocation t(15;17) and blocks 
promyelocytic differentiation (Zelent et al., 2001).  In primary human APL cells 
PML-RARα inhibits C/EBPα function by downregulating its expression. AML 
specific Flt3 mutations also downregulate C/EBPα expression and hence 
contribute to the leukemic phenotype (Zheng et al., 2004). C/EBPα is not only 
inhibited at the protein level, but also at the mRNA level. Perrotti et al., have 
demonstrated that in growth factor-independent cell lines expressing BCR-ABL 
and in primary bone marrow cells from individuals with CML blast crisis, 
C/EBPα expression is suppressed at the translational level by a mechanism that 
depends on the specific interaction of the RNA-binding protein hnRNP E2 with 
the cytosine-rich intercistronic region of CEBPα mRNA. In fact, ectopic 
expression of C/EBPα in cells expressing BCR-ABL allows G-CSF-induced 
differentiation; by contrast, overexpression of hnRNP E2 in myeloid precursor 
cells downregulates expression of C/EBPα and G-CSFr and promotes rapid cell 
death upon culture of these cells in G-CSF containing medium (Perrotti et al., 
2002). In addition, Timchenko et al. have shown that calreticulin downregulates 
C/EBPα by inhibiting CEBPα mRNA (Timchenko et al., 2002). In some AML 
cases CEBPα hypermethylation leading to its gene inactivation has also been 
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reported. Several studies demonstrate that C/EBPα protein activity is modulated 
by post translational modifications (Behre et al., 2002b). SUMOylation of 
C/EBPα in its synergy control motif provides a means to rapidly control higher 
order interactions among transcription factors and suggests that SUMOylation 
may be a general mechanism to limit transcriptional synergy (Subramanian et 
al., 2003). Phospho modification of C/EBPα at Ser21 in the transactivation 
domain inhibits granulopoiesis (Ross et al., 2004) while phosphorylation at Ser299 
in the DNA binding domain attenuates its DNA binding activity leading to its 
inactivation and inhibition of granulopoiesis (Charles W. Mahoney, 1992).  
 These studies point to a crucial role of C/EBPα in both normal myeloid 
differentiation and leukemogenesis. However, how the transcriptional activity of 
C/EBPα is regulated both in normal myelopoiesis as well as in leukemogenesis 
is not fully understood. Recent reviews focusing on disruption of differentiation 
in AML have set the perspective for the future research in this field. Many 
questions remain unanswered regarding the transcriptional regulation of 
granulocyte and monocyte development. What are the relative contributions of 
different lineage specific factors in a particular lineage commitment, how do 
they operate within regulatory networks to orchestrate lineage selection and 
haematopoietic development?, What is the role of lineage specific transcription 
factors on stem cells, and how does this relate to AML. Do some granulocyte or 
monocyte progenitors develop directly from pluripotent stem cells; how 
irreversible are commitment decisions? Are there additional transcription factors 
yet to be revealed; are there lineage-restricted co-activators or co-repressors 
which participate in lineage specification? Detailed studies for further 
clarification of the regulatory network are needed. Another important area for 
the investigation is the further identification of protein-protein interactions to 
find out if there is a switch between different interacting partners of C/EBPα in 
normal haematopoiesis and AML as seen in case of young and old mice livers 
(Iakova et al., 2003). The answers to these questions will provide general 
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lessons in developmental biology and insights into leukemogenesis and will 
enable applications in clinical haematology, oncology, and gene therapy 
(Friedman, 2002; Frohling and Dohner, 2004; Tenen, 2003). 
 
1.6 c-Jun NH2-terminal kinase (JNK):   
The transmission of extracellular signals into intracellular responses is a 
complex process which often involves the activity of mitogen-activated protein 
kinases. Mitogen-activated protein (MAP) kinase signalling pathways relay, 
amplify and integrate signals from a diverse range of extracellular stimuli; 
thereby the genomic and physiological response of a cell to changes in the 
respective environment (Weston and Davis, 2002). Each MAPK is activated by 
dual phosphorylation on a Thr- Xaa-Tyr motif by upstream kinases referred to as 
MAPK kinase or MKKs. Biochemical studies led to the identification and 
purification of JNK as a "p54 microtubule-associated protein kinase" that was 
activated by cycloheximide (Kyriakis and Avruch, 1990). 
 JNK was found to bind the NH2-terminal activation domain of c-Jun (Hibi 
et al., 1993) and to phosphorylate c-Jun on Ser-63 and Ser-73 (Woodgett et al., 
1993) leading to increased transcriptional activity. JNK is activated by the 
treatment of cells with cytokines (e.g., TNF and IL-1) and by exposure of cells 
to many forms of environmental stress e.g., osmotic stress, redox stress, and 
radiation (figure 4). A major target of the JNK signalling pathway is the 
activation of the AP-1 (Activator protein-1) transcription factor that is mediated, 
in part, by the phosphorylation of c-Jun and related molecules implicated in 
regulating altered gene expression, cellular survival and proliferation in response 
to cytokines, growth factors, to noxious stimuli and to oncogenic transformation 
(Davis, 2000; Dong et al., 2001; Manning and Davis, 2003); (Fuchs et al., 
1998d). Figure 4 schematically depicts JNK kinase signalling pathway.  
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Fig 4. SAPK/JNK signalling cascades: Stress-activated protein kinases (SAPK)/Jun N-
terminal kinases (JNK) are members of the MAPK family and are activated by a variety of 
environmental stresses, inflammatory cytokines, growth factors and GPCR agonists. Stress 
signals are delivered to this cascade by members of small GTPases of the Rho family (Rac, 
Rho, cdc42). As with the other MAPKs, the membrane proximal kinase is a MAPKKK, 
typically MEKK1-4, or a member of the mixed lineage kinases (MLK) that phosphorylates 
and activates MKK4 (SEK) or MKK7, the SAPK/JNK kinases. Alternatively, MKK4/7 can be 
activated by a member of the germinal center kinase (GCK) family in a GTPase-independent 
manner. SAPK/JNK translocates to the nucleus where it regulates the activity of several 
transcription factors such as c-Jun, ATF-2 and p53 (Leppa et al., 1998) Adapted from cell 
signalling technology. 
. 
 
1.6.1 JNK signalling in human leukemia and tumour development: 
Dramatic advances have occurred over the last few years in the research of MAP 
kinases in haematological malignancies. The realization that map kinase – 
dependent signalling cascades play important roles in the regulation of apoptosis 
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and growth of malignant hematopoietic cells has led to extensive studies, aimed 
to characterize the precise mechanisms that are responsible for such effects 
(Milella et al., 2001). It is now clear that the Raf/MEK/ERK pathway 
participates in the generation of mitogenic responses in essentially all 
hematopoietic malignancies, including acute and chronic leukemias, lymphomas 
and multiple myeloma (Davis, 2000; Kennedy and Davis, 2003; Manning and 
Davis, 2003; Milella et al., 2001; Weston et al., 2002). On the other hand, the 
regulatory effects of the JNK and p38 MAP kinase pathway in acute myeloid 
leukemias are not well understood. A recent report demonstrated a relationship 
between the constitutive activity of JNK in leukemic blasts and treatment failure 
in acute myelogenous leukemia (Cripe et al., 2002). However owing to its 
important biological function in activation of the gene transcription and inducing 
apoptosis, the JNK signalling pathway is often involved in pathogenesis of 
cancer. In a recent study, inducible activation of JNK in APL cells harbouring 
PML-RARα induced apoptosis of NB4 cells. This suggests a possible role of 
JNK in myeloid leukemia (Davison et al., 2004). 
 JNK also seems to play a significant role in tumour development (Johnson 
et al., 1996). In fact, several tumour cell lines have been reported to possess 
constitutively active JNK (Ip and Davis, 1998). The transforming potential of 
several oncogenes is reduced after introduction of antisense JNK 
oligonucleotides or dominant-negative versions of proteins belonging to the 
JNK-pathway. This indicates that JNK activity is necessary for efficient 
transformation and tumourigenesis by oncogenes (Kennedy and Davis, 2003; 
Manning and Davis, 2003; Potapova et al., 2000; Potapova et al., 1997). 
However, in a recent study, fibroblasts isolated from mice that lack expression 
of JNK due to compound mutations of Jnk genes were efficiently transformed 
by Ras, and actually formed increased numbers of tumour nodules and the size 
of individual tumours in mice injected with these cells (Kennedy et al., 2003). 
Taken together these studies suggest that JNK could play more than one role in 
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tumour development, and that in certain cases this role might be to promote or 
inhibit tumour development. Understanding the genetic and mechanistic basis 
for these different roles of JNK in tumours may pave the way for potential 
therapeutic approaches (Davis, 2000; Dong et al., 2001; Manning and Davis, 
2003). 
1.6.2 Stress activated kinases regulate protein stability: 
In addition to their function in signal transduction, SAPK kinases have been 
implicated in the regulation of protein stability (Musti et al., 1997). The 
mechanisms that modulate ubiquitination by stress signals are: association with 
auxiliary proteins, phosphorylation by specific kinases, and a combination of 
both. Therefore, changes in ubiquitination would depend on the conformation of 
a specific substrate and its associated proteins (Fuchs et al., 1998d). 
Ubiquitination dependent protein degradation has been shown to participate in 
regulating several stress activated transcription factors (Alarcon-Vargas and 
Ronai, 2004; Fuchs et al., 1998a; Fuchs et al., 1998b; Fuchs et al., 1998c; Fuchs 
et al., 1997; Isaksson et al., 1996). Cellular responses to stress and damage, as 
well as mitogenic stimuli, initiate signal transduction cascades that modify the 
duration and magnitude of transcriptional activity of stress-responsive and 
mitogen-regulated transcription factors. The resulting changes in gene 
expression are implicated in differentiation or proliferation and apoptosis 
(Alarcon-Vargas and Ronai, 2004; Fuchs et al., 1998b; Fuchs et al., 1998c; 
Fuchs et al., 1998d). 
 Among stress responsive kinases, JNK1 regulates a different subset of 
substrates by acquiring a specific phosphorylation pattern that affects 
conformation, stability, subcellular localization and transcriptional activation 
(Fuchs et al., 1998c; Fuchs et al., 1996; Fuchs et al., 2000; Musti et al., 1997). 
Phosphorylation of JNK associated proteins prevent their targeting by 
ubiquitination through possible changes in their conformation which is expected 
to abrogate the association of the respective ubiquitin ligase (Fuchs et al., 1997; 
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Sabapathy et al., 2004). The emerging model from recent observations suggests 
that JNK, by virtue of its targeting ubiquitination, is the key regulator of 
associated proteins, c-jun, ATF2, c-Myc, p53, and Jun B in non-stressed normal 
growing cells. After stress, JNK´s activation by upstream kinases, followed by 
phosphorylation of its associated substrates, regulates their stability and activity 
(Alarcon-Vargas and Ronai, 2004; Fuchs et al., 1998b; Fuchs et al., 1998c; 
Fuchs et al., 1996; Fuchs et al., 2000; Fuchs et al., 1997; Musti et al., 1997; 
Musti et al., 1996). 
 
1.7 Proteomics:  
The array of proteins found within the cell, their interactions and modifications 
hold the key to understanding biologic systems. This is encapsulated in the term 
"proteome." It can be defined as the protein population of a cell, characterized in 
terms of localization, post translational modification, interactions, and turnover, 
at any given time. The proteome is fundamentally dynamic and has an inherent 
complexity that surpasses that of the genome or the mRNA complement found 
within a cell (Cristea et al., 2004). Analysis of the whole proteome of a cell by 
isolating individual proteins on 2-Dimensional gel or by liquid chromatography 
subsequently followed by their identification by mass spectrometry comprises 
proteomics. Recent success illustrates that mass spectrometry based proteomics 
is an indispensable tool for molecular and cellular biology and for the emerging 
field of systems biology (Aebersold and Mann, 2003). Proteomics-based 
approaches, which enable the quantitative investigation of both cellular protein 
expression levels and protein-protein interactions involved in signalling 
networks, promise to define the molecules controlling the processes involved in 
cancer (Simpson RJ, 2001). Owing to its high throughput, MS-based proteomics 
has been extensively applied for probing molecular mechanisms in signal 
transduction, identifying cancer biomarkers and profiling various diseases (Celis 
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and Gromov, 2003; Celis et al., 2004; Jain, 2002; Michaud and Snyder, 2002; 
Wang et al., 2004). 
 Proteins are important targets for drug discovery and may also be of 
prognostic importance which can be treated as diagnostic and prognostic factor 
(Jain, 2002). Moreover, aberrant regulation and function of transcription factors 
has been reported to be involved in the pathogenesis of AML (Chava Parry, 
2002; McKnight, 2001; Nerlov, 2000; Pabst et al., 2001b; Pedersen et al., 2001; 
Perrotti et al., 2004; Rangatia et al., 2002; Timchenko, 2003; Vangala et al., 
2003; Westendorf et al., 1998; Zheng et al., 2004). Mapping of protein 
interactions of crucial transcription factors can highlight new functions of a 
known protein or can even define the function of novel proteins (Figeys, 2002; 
Michaud and Snyder, 2002). Few years back yeast two-hybrid was the method 
of choice to screen protein-protein interactions but, nowadays this has been 
replaced by high throughput mass spectrometry (MS) based proteomics which is 
extensively being used for screening targets as well as interacting proteins. 
Proteomics, a qualitative and quantitative method has been the technique of 
choice to identify target and interacting proteins (Mann et al., 2001; Pandey et 
al., 2000). Proteomics encompasses many platform technologies (figure 5) for 
protein separation and identification, for determining their biomolecular 
interactions, function, and regulation, and for annotating, storing, and 
distributing protein information  (Aebersold and Goodlett, 2001; Celis and 
Gromov, 2003; Celis et al., 2004; Figeys, 2002; Figeys, 2003; Gavin et al., 
2002; Panisko et al., 2002).  
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Fig 5. Technology and resources in proteomics: Technologies and resources in proteomics 
encompasses many platform technologies for protein separation and identification, for 
determining their biomolecular interactions, structure, function, and regulation, and for 
annotating, storing, and distributing protein information. In the context of translational cancer 
research, proteomics requires well-established tissue banks as well as tools from genomics 
and transcriptomics Adapted from molecular´s biologists guide for proteomics (Graves and 
Haystead, 2002). 
  
 
1.8 Aim of the study: 
Mechanisms underlying the inactivation of C/EBPα function in acute myeloid 
leukemia are poorly understood.  Recent findings suggest that protein-protein 
interactions play a pivotal role in normal functioning of lineage specific factors. 
Hence, the objective of the present study is to identify and characterize 
interacting proteins of C/EBPα which might modulate C/EBPα protein function. 
For this purpose we used the GST fused DNA binding domain of C/EBP 
proteins and performed GST-pull down assays for isolating the interacting 
proteins and further identifying them with the mass spectrometer. 
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2. Materials and Methods:  
2.1 Materials: 
2.1.1 Mammalian Cell Lines:  
293T cells (human embyronic kidney fibroblast cells) 
U937 (human myeloid cell line, monoblastic) 
Myelomonocytic HL60 cells 
K562 ER-C/EBPα (Erythroleukemic cells stably transfected with C/EBPα-ER   
fusion vector) 
NB4 cells (Acute promyeloblastic cell line carrying PML-RARα fusion Gene)  
Cells from different AML patients for western blot analysis were kindly 
provided by the laboratory for leukemia diagnostic, Med III Klinikum 
Großhadern, University of Munich, Germany.  
2.1.2 Cell Culture: 
RPMI (PAA, Cölbe, Germany) 
RPMI without Phenol red (PAA, Cölbe, Germany) 
Foetal bovine serum (Invitrogen/GIBCO, Germany) 
Penicillin/Streptomycin (GIBCO, Germany) 
Charcoal treated FBS (Hyclone, Greiner, Nürtingen, Germany) 
Dialysed FBS (SIGMA, Germany) 
DPBS   (PAN, Germany) 
DMEM (PAN, Germany) 
Trypsin EDTA (GIBCO, Germany) 
β-Estradiol (SIGMA, Germany)              
2.1.3 Immunoblots: 
GST sepharose beads 4B (Amersham Biosciences, USA) 
Protein agarose beads (Roche Molecular Diagnostics, Germany) 
Phosphatase inhibitor Cocktail I and II (Sigma, Germany) 
Protease inhibitors (Sigma, Germany) 
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8 and 10% SDS PAGE (Acryl amide; Roth, Germany) 
Bradford assay buffer (Biorad Laboratories, Germany) 
Nitrocellulose membrane (Millipore, Germany)  
ECL detection kit (Amersham Biosciences, Germany)  
ECL hyperfilm (Amersham Biosciences, Germany) 
2.1.4 Antibodies:  
Anti-C/EBPα (cat# sc-61 and sc-61X for Gelshift; Santa Cruz Biotechnology, 
CA, USA) 
Anti-β-tubulin (cat# sc-9104 Santa Cruz Biotechnology, CA, USA) 
Anti-JNK1 (cat# sc-474 Santa Cruz Biotechnology, CA, USA) 
Anti-pJNK1 (cat# 9251S Cell Signalling Technology, USA) 
Anti-pc-Jun (cat# 9261S Cell Signalling Technology, USA) 
Anti-GST (cat# sc-131 Santa Cruz Biotechnology, CA, USA) 
Anti-PU.1 (cat# sc-5972 Santa Cruz Biotechnology, CA, USA) 
Anti-HA (cat# 3F10, Roche Molecular Diagnostics, Germany)     
2.1.5 2D-gel Electrophoresis: 
Urea plus (Amersham biosciences, Germany) 
Resolyte buffer (Rehydration buffer; Amersham Biosciences, Germany) 
Bromophenol blue (Sigma, Germany) 
Immobilin dry strips (IPG strips, pH 3-10, Amersham Bioscience, Germany) 
Colloidal Coomassie blue G-250 (Sigma, Germany) 
Bromophenol Blue (Sigma, Germany) 
2.1.6 Peptide Extraction: 
50% and 70% Acetonitrile and 50mM Ammonium Bicarbonate (NH4HCO3) for 
washing and fixing the gel pieces 
Trypsin enzyme reconstituted with 50mM Ammonium Bicarbonate (NH4HCO3).   
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Lyophilized peptides dissolved in solution containing 20% Acetonitrile and 
0.1% Trifluoroacetic acid (TFA).  
DHB matrix solution of 9:1 ratio of DHB: HMB 
2.1.7 Mass Spectrometry: 
Reflex III MALDI-TOF for Peptide mass fingerprints i.e PMF (Bruker 
Daltonics, Leipzig, Germany)     
AB4700 MALDI-TOF/TOF for MS/MS analysis and GPS explorer software for 
spectral annotation (Applied Biosystems, Darmstadt, Germany) 
Mascot database search (Matrix Science) 
AnchorChip plate (Bruker Daltonics, Leipzig, Germany) 
2.1.8 Chemicals: 
2,5-Dihydroxy-Benzoic Acid (Sigma Aldirch, USA) 
2-Hydroxy-5-Methoxy-Benzoic Acid (Sigma Aldirch, USA) 
Acetonitrile (Sigma Aldirch, USA) 
Acetic Acid (Merck, Darmstadt, Germany) 
Ammonium Bicarbonate (Sigma, USA) 
Anisomycin (Calbiochem, Germany) 
Colloidal Coomassie Blue G-250 (Sigma, Germany) 
Dimethyl Sulfoxide (Sigma, USA) 
Dithioerythritol (Merck, Darmstadt, Germany) 
Dithiothreitol (Merck, Darmstadt, Germany) 
Deoxycholate (Merck, Darmstadt, Germany) 
Ethanol (Merck, Darmstadt, Germany) 
Formaldehyde (Merck, Darmstadt, Germany) 
Ethylenediamine Tetra-Acetic Acid (Merck, Darmstadt, Germany) 
Ethylene Glycol bis (2-aminoethyl ether)-N,N,N'N'-Tetra acetic Acid 
(Merck, Darmstadt, Germany) 
Formaldehyde (Merck, Darmstadt, Germany) 
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Glycine (ICN Biomedicals) 
Glycerol (Merck, Darmstadt, Germany) 
Isopropanol (Merck, Darmstadt, Germany) 
JNK inhibitor SP600125 (Calbiochem, Germany) 
Methanol (Merck, Darmstadt, Germany) 
Silver Nitrate (Merck, Darmstadt, Germany) 
Sodium Carbonate (Merck, Darmstadt, Germany) 
Sodium Chloride (ICN Biomedicals) 
Sodium Thiosulfate (Merck, Darmstadt, Germany) 
Sodium Dodecyl Sulphate (SDS) (Sigma, USA) 
Trifluoroacetic Acid (TFA) (Merck) 
Triton X-100 (Sigma, USA) 
Tween-20 (Sigma, Germany) 
Urea Plus (Merck, Darmstadt, Germany) 
2.2 Methods: 
2.2.1 GST-Purification: 
We used plasmid constructs in which full length C/EBPα and regions 
comprising amino acids 270 to 358 encoding the DNA binding domain of 
C/EBP (conserved in all C/EBP family proteins) are cloned in frame with the 
Glutathione-S-Transferase (GST) in a pGEX bacterial expression vector 
(Amersham Biosciences, Germany). Fusion proteins were expressed in 
transformed DH5α E. coli bacterial strains after 0.5mM IPTG induction for 2 
hours. Induced bacterial pellet was lysed in NETN buffer {150mM NaCl, 20mM 
Tris pH 8.0, 1mM EDTA pH 8.0, 0.1% NP40 and protease inhibitors (Sigma)} 
and sonicated, followed by subsequent protein purification using immobilised 
Glutathione Sepharose 4B beads (Amersham Biosciences, USA). Sepharose 
beads bound with GST proteins were washed twice with NETN buffer on a 
rotating shaker at 4°C for 10 minutes each and then lysed in 2X SDS sample 
loading buffer (125mM Tris pH 6.8, 4% SDS, 20% Glycerol, 10% 2-Mercapto-
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ethanol and pinch of bromophenol blue). Subsequently proteins were separated 
on 12% SDS PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis) and visualised by Coomassie blue staining. 
 
2.2.2 GST-Pull Down: In the present study, we used the myelomonocytic U937 
cell line as our model system. Nuclear extract from U937 cells was prepared 
using lysis buffer A (20mM Tris pH 8.0, 10mM NaCl, 3mM MgCl2, 0.1% 
NP40, 10% Glycerol, 0.2mM EDTA and Protease inhibitors 1µg/ml) and lysis 
buffer C (20mM Tris pH 8.0, 400mM NaCl, 0.2mM EDTA, 20% Glycerol, 
1mM DTT and 1µg/ml Protease inhibitors). Equal amounts of bacterially 
purified proteins were incubated with 500µg of nuclear extract (volume made up 
to 1ml with NETN buffer) for 3h at 4°C. After pull down, protein bound beads 
were washed 3 times with NETN buffer at 10 rpm on a rotating shaker for 5 
minutes at 4°C. Beads were lysed in urea lysis buffer (66% Urea plus one, 1% 
DTE, 4% CHAPS, 2.5mM EDTA, 2.5mM EGTA) to completely denature the 
interacting proteins which were then applied for 1D and 2D separation in a pH 
range of  3-10. In addition, S35-Methionine labelled in-vitro translated JNK1 was 
pulled down with GST-fusion proteins by incubating for 3 hours, separated on 
10% SDS PAGE and detected by autoradiogram using Kodak films. 
 
2.2.3 2D-Gel Electrophoresis: GST and GST-DBD were incubated with 
nuclear extracts of the myelomonocytic cell line U937. Beads with their 
associated proteins from nuclear extract were lysed in urea lysis buffer for 1h at 
RT on a rotating shaker. Lysed beads were passed through an RNA quiashredder 
(Quiagen, Germany), and resulting supernatant containing dissolved proteins 
was ultracetrifuged for 50 minutes at 50,000 rpm at 22°C to get rid of DNA and 
other cellular debris. In the first dimension, 350µl of dissolved proteins after 
ultracentrifugation were separated on an immobilineTM dry strip pH 3-10 
(Amersham Biosciences, Germany) by isoelectric focussing (IEF) where 
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proteins are separated on the basis of their isoelectric point (pI). The reduction 
and alkylation of separated proteins was carried out in urea buffer containing 2% 
DTE and 2.5% iodoacetamide, respectively. Proteins were then separated in the 
second dimension using 12% SDS PAGE on the basis of their size (relative 
molecular weight). 2D gels were silver stained to visualise the protein spots. 
 
2.2.4 MALDI-TOF Mass Spectrometry: On comparison of the two silver 
stained gels, differentially appearing protein spots from GST-DBD gel were 
carefully excised, destained and in gel digestion was performed with 200ng 
trypsin (Promega) in ammonium bicarbonate solution for 16 hours. The digested 
peptides were eluted in 70% acetonitrile, lyophilised and resuspended in 5µl of 
0.1% TFA in 10% acetonitrile. The dissolved peptides were mixed in 1:1 ratio 
with DHB (2, 5-dihydroxybenzoic acid) matrix solution and loaded on an 
anchorChip target plate (BRUKER DALTONICS, GERMANY). Peptide mass 
fingerprint (PMF) was generated by Matrix Assisted Laser Deionization-Time 
Of Flight (MALDI TOF; REFLEX III, BRUKER DALONICS) mass 
spectrometry and corresponding proteins were identified by a MASCOT 
database search (Matrix Sciences). 
 
2.2.5 Plasmid Constructs: In this article we used pCDNA3-MKK7, pCDNA3-
MEKK1-flag (kind gift from Dr. Roger Davis); GST, GST-DBD, GST-C/EBPα 
(kind gift from Dr. Claus Nerlov); C/EBPα-GZ, (Leucine zipper replaced with 
leucine zipper of yeast GCN4), BR3 basic region (Amino acids: 297R, 298K, 
300R, and 302K of C/EBPα mutated to Glycine, Threonine, Glycine and 
Aspargine respectively); L1,2 (Leucine 1 and 2 form leucine zipper mutated to 
alanine) was kindly provided by Dr. Alan Friedman and is described elsewhere 
(Landschulz et al., 1989); pCDNA3-humanC/EBPα was previously described 
(Pabst et al., 2001b), GST-c-Jun corresponding to 35 kDa  (1-79 amino acids 
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fused with GST) was bought from Cell Signalling technology while bacterially 
purified GST-c-Jun (40kDa) was a kind gift from Dr. Arndt Keiser. 
 
2.2.6 Cell Culture: U937 and HL 60 cells were cultured in RPMI supplemented 
with 10% heat inactivated foetal bovine serum (GIBCO, Aidenbach, Germany) 
and 1% Penicillin-Streptomycin (GIBCO, Aidenbach, Germany); human 
embryonic kidney 293T cells were maintained in Dulbecco´s modified Eagle 
medium (DMEM; GIBCO) supplemented with 10% foetal bovine serum (FBS), 
1% glutamine, and 1% Pen/strep (GIBCO); NB4 cells were maintained in RPMI 
supplemented with 20% FBS, 2.5% Penicillin-Streptomycin and 2.5% 
glutamine. K562 Er-C/EBPα and K562Er cells were maintained in RPMI 
without phenol red supplemented with 10% charcoal treated FBS (Hyclone, 
USA) and 2µg/ml Puromycin (ICN Biochemicals). 
 
 2.2.7 Co-Immunoprecipitation: Co-immunoprecipitation is an in-vitro 
biochemical assay which we used to detect in-vivo interaction of C/EBPα with 
JNK1. Here we used 25µl slurry of protein A agarose beads (Roche Molecular 
Diagnostics, Germany) and 2µg of the anti JNK1 antibody (Santa Cruz 
Biotechnology) to immunoprecipitate JNK1 from whole cell extracts of the 
myeloid cell line U937 using co-immunoprecipitation buffer (1X TBS, 0.5% 
NP40 and protease inhibitors). Immunoprecipitated proteins were heated at 56°C 
for 90 minutes in 2X SDS loading buffer and then boiled at 95°C for 5 minutes. 
Denatured proteins were subsequently separated on 8% SDS PAGE and 
immunoblotted against rabbit polyclonal anti-JNK1 and anti C/EBPα antibody 
(Santa Cruz Biotechnology) as required after transferring to a PVDF immobilon-
P membrane.  
                                                                                                                                                      
2.2.8 In-vitro Kinase Assay: To analyse whether JNK1, a substrate specific 
kinase, phosphorylates C/EBPα, an in-vitro kinase assay was performed using 
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GST-DBD as substrate and JNK1 as kinase which was previously immuno-
precipitated using an anti-HA antibody (Roche Molecular Biochemicals, 
Germany) from a whole cell extract of 293T cells co-transfected with C/EBPα 
and MEKK1; proteins bound to beads after immunoprecipitation were 
equilibrated with kinase buffer. GST c-Jun (1-79 amino acids of c-Jun 
containing S63 and S73; Cell Signalling Technology) a known substrate of 
JNK1 was used as positive control. Kinase reaction was performed for 30 
minutes at 30°C using 1X kinase buffer (Cell Signalling Technology), 4µCi 
[γP32]ATP (3000Ci/mMol), 50µM ATP, 10µl GST-DBD and immuno-
precipitated HA-JNK1. After 30 minutes the reaction was terminated using 2X 
SDS loading buffer. The proteins were separated on 10% SDS PAGE and 
visualised by autoradiography. 
 
2.2.9 Identification of Phosphopeptides by Mass Spectrometry: In order to 
identify phosphopeptides from tryptic peptides of C/EBPα, immunoprecipitated 
C/EBPα from 293T alone and co-transfection of C/EBPα and MKK7 was 
separated on 10% SDS PAGE and excised bands were sent to Toplab (Munich, 
Germany) for further analysis. Both protein bands were digested with the 
protease trypsin and MALDI MS was done to make identification. For database 
search, the program MS Fit (Protein Prospector) was used with the NCBI 
database (release 210604). Two protein bands, control (Ip C/EBPα from 293T) 
and protein of interest (Ip C/EBP from 293T cotransfected with C/EBPα+ 
MKK7) were clearly identified as the CCAAT/enhancer binding protein alpha 
(NCBI Accession # 28872794, 37.6 kDa, pI 7.3) from Homo sapiens. In a 
further process the digested sample of the possibly phosphorylated C/EBPα was 
incubated for 2h with bovine alkaline phosphatase (0.1u/µl /2h /30°C) to remove 
phosphorylation of peptides. A direct comparison of the three MALDI spectra 
CCAAT (control), CCAAT (phosphorylated) and CCAAT (phosphorylated + 
alkaline phosphatase) confirmed the presence of a phosphopeptide. The mass of 
 38
the non-phosphorylated peptide is 1466.74Da with the sequence (K)SVDKNSN 
EYRVR(R) (Start: 277 / End: 288).  
 
2.2.10 Electrophoretic Mobility Shift Assay (EMSA): To assess C/EBPα 
DNA binding activity, a double-stranded G-CSF receptor promoter oligo-
nucleotide extending from bp -57 to -38 was used as a probe (Smith et al., 
1996). EMSA was performed by incubating 5µg of nuclear extract with 1ng of 
the radiolabelled probe in binding buffer [10 mM HEPES pH 7.9, 50 mM KCl, 
2.5 mM MgCl2, 1mM dithiothreitol (DTT)], 10% glycerol and 0.5µg of poly dI-
dC (Amersham Biosciences, Germany) for 30 minutes at room temperature. For 
competition experiments, a 50-fold excess of unlabeled competitor oligo-
nucleotide was added before addition of the labelled oligonucleotide. For 
supershift experiments, 1.0µl of specific C/EBPα antisera (Santa Cruz 
Biotechnology, CA USA) were added before addition of the radiolabelled probe. 
Complexes were resolved in 5.2 % non-denaturing polyacrylamide gels in 1X 
TBE buffer. Oligos used were OligoA (AAG GTG TTG CAA TCC CCA GC) 
and OligoB (GCT GGG GAT TGC AAC ACC TT; Metabion, Germany). 
Nuclear extracts used for EMSA were prepared from transiently transfected 
293T cells with expression plasmids of hC/EBPα (human C/EBPα), JNK1 and 
MEKK1. 
 
2.2.11 Transient Transfections using LipofectAMINE Plus and Reporter 
Assays Firefly and Renilla Luciferase: 293T cells were transiently transfected 
using LipofectAMINE Plus (Invitrogen Life Technologies, Germany) as 
described by the manufacturer. Firefly luciferase activities from the constructs 
phC/EBPα, pCDNA3-MEKK1, pTK, p(C/EBP)2TK and Renilla luciferase 
activity from the internal control plasmid pRL-null were determined 24 h after 
the initiation of the transfection protocols using the Dual-Luciferase Reporter 
Assay System (Promega, Germany). Firefly luciferase activities were normalized 
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to the Renilla luciferase values of pRL-null.  Results are given as means ± 
S.E.M. of three independent experiments. The following DNA concentrations of 
the reporter constructs and expression plasmids were used for LipofectAMINE 
Plus transfections: 0.1 µg of pCDNA3-hC/EBPα, pCDNA3-MEKK1, pTK and 
p(C/EBP) 2TK each; 0.01 µg of the internal control plasmid pRL-null; and the 
same concentrations of the empty expression vectors were used as controls, 
respectively.  In the transfections without cotransfection of MEKK1, the empty 
vector pCDNA3 was included to equalize the amount of DNA in each 
transfection set.  pRL-null was chosen as internal control plasmid, because it 
was not transactivated by Ras in 293T cells which in general activates the pTKα 
promoter in the presence of C/EBPα (Behre et al., 2002b; Behre et al., 1999a) 
 
2.2.12 In-vivo HA Ubiquitination Assay: 1*106 293T cells were transiently 
transfected with different constructs as described (figure 12A), 24 h post 
transfection cells were lysed in RIPA buffer, and C/EBPα was immuno-
precipitated from 500µg protein, as described before in this article. HA-
Ubiquitin was a kind gift from Dr. Bohmann (Musti et al., 1997) . 
 
2.2.13 Pulse Chase Labelling: 3*105/ml HL60 cells were plated in 50ml 
normal RPMI medium (RPMI supplemented with 10% FBS and 1 % Pen/Strep) 
one day before the experiment. In the next day cells were washed twice with 
PBS and grown in 3ml labelling medium (RPMI without methionine and 
cysteine, supplemented with 0.2% dialysed FBS; Sigma USA) together with 
200µCi [S-35]-methionine/ml for 15 minutes with constant shaking at 37°C in a 
water bath. The cells were then washed to remove labelling medium and were 
chased for various time points as indicated (figure 12B) with normal RPMI 
medium in the absence or presence of 50ng anisomycin. The cells were lysed in 
RIPA buffer supplemented with protease inhibitors, and then lysates were 
subjected to immunoprecipitation with a C/EBPα antibody. The resulting 
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precipitates were separated on 10% SDS PAGE followed by autoradiography 
and densitometry analysis. 
 
2.2.14 Western Blotting: 24 h post-transfection, whole cell extract was prepared 
with RIPA buffer (1% NP40, 0.5% Sodium Deoxycholate (DOC), 0.1% SDS, 
150mM NaCl, 5mM EDTA, 50mM Tris pH 8.0 and 1µg/ml Protease Inhibitors). 
Equal amount of total protein was denatured in the SDS sample loading buffer, 
separated on 10% SDS-polyacrylamide gels and transferred to an immobilon-P 
membrane (Millipore, USA). The membranes were incubated with anti-C/EBPα 
antibody (dilutions; Santa Cruz Biotechnology) or anti-β−tubulin antibody as an 
internal control (Roche Molecular Biochemicals) for 1-3h and horseradish 
peroxidase conjugated to secondary antibodies (Amersham Biosciences, 
Germany) for 1h. Signals were detected with the ECL Western blotting detection 
reagents (Amersham Biosciences, Germany). In parallel, Anisomycin 
(Calbiochem, Germany) treated (25ng/ml) myeloid HL60 cells for 30, 60 and 90 
minutes were lysed in RIPA buffer and immunoblotted against the 
C/EBPα antibody. In the experiment with cycloheximide treatment, U937 cells 
were treated with 50µg/ml cycloheximide prior to treatment with 25ng/ml 
anisomycin, whole cell extract was prepared and equal amount of protein was 
separated. In all immunoblotting experiments a 1:1000 dilution for primary and 
1:2000 dilutions for secondary antibody was used. 
3. Results: 
 
3.1 Purification of GST fusion constructs: In order to understand the 
molecular mechanism underlying C/EBPα inactivation in patients with acute 
myeloid leukemia (AML), we applied proteomics based mass spectrometry to 
identify the interacting proteins of C/EBPα which might be important in AML 
pathogenesis. Figure 6A depicts the location of characterized functional domains 
within the CCAAT/enhancer-binding protein (C/EBP); BR-LZ DNA-binding 
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domain (DBD) is required for dimerization and DNA binding. The three 
transactivation elements TE-I, TE-II and TE-III mediate interactions with the 
transcriptional machinery; GST fused to wild type C/EBPα and the DNA 
binding domain of C/EBP was used in this study.  
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Fig 6. Bacterial purification of GST fusion proteins: A) The location of characterized 
functional domains within the CCAAT/enhancer-binding protein (C/EBP) protein. The basic 
region leucine zipper (BR-LZ) has been shown to mediate protein interaction with other 
transcription factors involved in lineage-specific gene regulation. The three transactivation 
elements TE-I, TE-II and TE-III mediate interactions with the transcriptional machinery 
(TBP/TFIIB; CBP/p300; SWI/SNF), GST fused with full length C/EBPα and DBD region of 
C/EBP is schematically depicted. B) Coomassie stained gel showing purified GST-C/EBPα, 
GST DBD, and GST proteins from E.coli after induction with IPTG. C,D) Physical activity of 
bacterially purified proteins was confirmed by immunoblotting against an anti PU.1 antibody 
after incubating them with ivt PU.1 (c) and nuclear extract (NE) of U937(d); PU.1 is known to 
bind DBD of C/EBPα . 
 
The Coomassie stained gel picture shows the purification of GST fused with the 
DNA binding domain of C/EBP (GST-DBD) and GST alone from bacterial 
culture after induction with IPTG (figure 6B). Physical activity of the bacterially 
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purified GST fusion constructs was confirmed by assessing their interaction with 
PU.1 which is known to bind with C/EBPα in its DNA binding domain (figure 
6C,D). 
 
3.2 2D Gel Electrophoresis of differentially interacting proteins: 
We next performed GST pull down assays using GST-DBD and GST from a 
U937 nuclear extract and separated the differentially interacting proteins in 2D 
gel (2-dimensional gel electrophoresis) after lysing the protein bound beads in 
the sample buffer described in materials and methods. 
 
GST + U937NE GST-DBD + U937NEpH3 10 pH3 10
220kDa
20kDa
1.JNK1
GST GST
JNK1
2
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Fig 7. 2D-Gel electrophoresis of differentially interacting proteins: GST and GST-DBD 
were incubated with nuclear extract of myelomonocytic cell line U937. Beads with their 
associated proteins from nuclear extract were lysed in urea lysis buffer (described in materials 
and methods). In the first dimension, 350µl of soluble proteins after ultracentrifugation were 
separated on immobilineTM dry strip pH 3-10 (Amersham Biosciences) by isoelectric 
focussing (IEF) where proteins are separated on the basis of their isoelectric point (pI). 
Proteins were then separated in the second dimension using 12% SDS PAGE on the basis of 
their size (relative molecular weight). 2D gels were silver stained to visualise the protein 
spots. 
 
Silver staining was done to visualise differentially interacting proteins in the 
GST-DBD gel (figure 7); protein spots present only in GST-DBD gel were 
excised and analysed by MALDI TOF mass spectrometry for identification. 
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Identified proteins are listed in table 4. We were not able to identify all proteins 
owing to their low amount and the sensitivity of mass spectrometer. 
 
Table 4: Interacting Proteins of C/EBPα identified by MALDI TOF Mass Spectrometry 
from GST-DBD gel. 
Accession No. Theoritcal Mol 
Mass (kDa) 
Description 
1.  JNK1   40.36 c-Jun N-Termnial Kinase rsidues 
2. Q9NQU5   75.00 p21 Activated Protein Kinase 
3. Q9UQ36 137.50 RNA Binding Protein Fragment human 
4. O78168   23.00 HLA-A 24* (var) 
5. Q96TA6   24.80 MADP-1 
6. Q8TD91   72.43 Hepatocellular Carcinoma Associated protein HCA2 
7. Q9P1U9   80.44 Zinc Finger Protein 45 
8. Q9UPN3 532.40 Macrophin 1 isoform fragment (homo sapiens) 
9. Q9NZT1   15.91 Calmodulin like skin protein 
 
 
3.3 JNK1 physically interacts with C/EBPα in-vitro:  
Among the identified interacting proteins of C/EBPα (table 4), we chose JNK 
for further characterization since JNK is known to regulate the activity of its 
physically associated substrates (Fuchs et al., 1997). To examine whether there 
is a direct protein-protein interaction between GST-DBD and JNK, we used 
GST-purified GST-DBD and incubated it with [35S]-methionine-labelled in-
vitro translated JNK1 for 90 minutes. After washing with stringent buffer, an 
interaction between JNK1 and GST-DBD was observed by autoradiography 
(figure 8A). As our major focus is C/EBPα, we next asked if JNK1 interacts 
with full length C/EBPα. We performed a GST-Pull down assay using GST-
DBD; GST-C/EBPα; and GST alone from 25ng/ml anisomycin induced 
(RIPA*) and uninduced U937 RIPA lysates, The immunoblot against JNK1 
shows a direct interaction of JNK1 and pJNK1 with GST-DBD and GST- 
C/EBPα; GST-c-Jun served as a positive control for this interaction (figure 8B).   
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Fig 8. C/EBPα physically binds to JNK1 in-vitro. A) GST pull-down assay was performed 
from [35S]-methionine-labelled in-vitro-translated JNK1 incubated with equal amounts of 
bacterially expressed GST-DBD (lane 6), GST (lanes 7) and sepharose beads (lane 3) GST-
DBD or GST was washed stringently and separated on SDS-PAGE prior to autoradiography. 
B) Immunoblot against JNK1 after GST pull down of JNK1 from a whole cell extract of 
anisomycin induced (RIPA*) and uninduced U937 cells shows an in-vitro interaction of JNK1 
with GST-C/EBPα, GST-DBD and positive control c-Jun while there is unspecific or no 
interaction with GST.  
 
3.4 JNK1 physically interacts with C/EBPα in-vivo: Next we asked if 
C/EBPα and JNK1 also interact in in-vivo, for this we performed JNK1 co-
immunoprecipitation using an anti JNK1 rabbit polyclonal antibody from whole 
cell extract of U937 cells. An immunoblot against JNK1 (upper panel) followed 
by C/EBPα (lower panel) after stripping the same membrane confirms an in-
vivo interaction of JNK and C/EBPα in myeloid cells (figure 9A). Since JNK 
interacts with DBD region of C/EBPα, We tried to narrow down DBD region 
interacting with JNK1 using already published DBD point mutants of 
C/EBPα (Liu H et al., 2003). Note that among these, two are  point mutants of 
DBD region while other is C/EBPα with its leucine zipper replaced with that of 
yeast GCN4 luecine zipper. Therefore, all the mutants have almost equal 
molecular weight (MW) of 42kDa like wild type C/EBPα. DBD mutants of 
C/EBPα used are described in materials and methods. 293T cells were 
separately cotransfected with various mutants and HA-JNK; 24h 
posttransfection, cells were lysed and JNK was immunoprecipitated with an 
Anti-HA antibody from 500µg protein. After separation on 10% SDS PAGE, 
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immunoblots with an anti HA antibody (upper panel) and then with C/EBPα 
antibody after stripping the same membrane  
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Fig 9. C/EBPα and JNK1 physically interact in-vivo: A) C/EBPα and JNK1 interaction 
was confirmed in-vivo in myeloid cell line U937 by co-immunoprecipitation of JNK1 from 
U937 nuclear extract using an anti JNK1 rabbit polyclonal antibody and immunoblotted with 
JNK1 (upper panel) same membrane stripped and reblotted with C/EBPα antibody (lower 
panel). B) JNK1 interacts with different C/EBPα DNA binding mutants; GZ, (Leucine zipper 
replaced with leucine zipper of yeast GCN4 protein), point mutants BR3 (basic region 
mutant)  and L1,and 2 form leucine zipper mutated to valine. Although phosphopeptide region 
271-288 identified later in this article is still intact in these mutants. 293T transfected with 
above mutants together with HA-JNK, cells were harvested and JNK1 was 
immunoprecipitated using an anti HA antibody (upper panel), same membrane stripped and 
reblotted with C/EBPα (lower panel). 
 
shows an interaction of JNK1 with all of these mutants (Lower panel), though 
with varying extent. However, later in this study we identified one 
phosphopeptide from tryptic digests of phosphorylated C/EBPα belonging to the 
DBD region which spans from amino acid 277-288. This region is still intact in 
the above used C/EBPα mutants (figure 9B) and could be the putative region of 
interaction with JNK1. 
 
3.5 JNK1 phosphorylates C/EBPα in-vitro:  
Because JNK1 is a potent kinase from the MAPK family (Manning and Davis, 
2003) and C/EBPα is known to be post translationaly modified by SUMO, 
ubiquitin and phosphorylation (Behre et al., 2002b; Mahoney et al., 1992; Ross 
et al., 1999; Ross et al., 2004; Subramanian et al., 2003) we asked if JNK1 also 
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modifies C/EBPα. For this, an in-vitro kinase assay using GST purified GST- 
C/EBPα as substrate and immunoprecipitated HA-JNK from transiently co-
transefected 293T together with MEKK1 as kinase shows that GST- C/EBPα 
can be phosphorylated by JNK1 (figure 10A; lane 1). After confirming the 
phospho modification of GST-C/EBPα as expressed and purified from bacteria, 
we assessed the phosphorylation of C/EBPα purified from transfected 293T 
cells. We performed an in-vitro kinase assay using immunoprecipitated C/EBPα 
from transiently transfected 293T as substrate and immunoprecipitated HA-JNK  
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Fig 10. JNK1 phosphorylates C/EBPα in in-vitro kinase assay: A) JNK1 phosphorylates 
bacterially purified GST-C/EBPα in an in-vitro kinase assay performed using GST-C/EBPα 
as substrate and HA-JNK1 as kinase (lane 1), GST-c-Jun (lane 3) served as positive control 
(upper panel); autoradiogram developed after 4 hours. Membrane immunoblotted with an anti 
HA antibody confirms the presence of kinase in each lane (lower panel) B) An in-vitro kinase 
reaction using immunoprecipitated C/EBPα from transiently transfected 293T as substrate 
and immunoprecipitated HA-JNK1 from transiently transfected 293T as kinase also confirms 
phosphorylation of C/EBPα (lane 3) while there is much less phosphorylation of 
C/EBPα with HA-JNK* (kinase dead) in autoradiogram (upper panel) developed after 4hrs, 
membrane immunoblotted with anti JNK1 shows kinase in all lanes (lower panel).  GST-c-
Jun, a known substrate of JNK1 used as positive control in the above assays was bacterially 
purified (kind gift from Dr.A Keiser); bacterially purified GST-c-Jun has mol. weight 40kDa. 
 
and HA-JNK* (from transiently cotransfected 293T together with MEEK1) as 
kinase. Wild type JNK phosphorylates C/EBPα (figure 10B; lane 3) while 
kinase dead HA-JNK could not (figure 10B; lane 5). GST-c-Jun (bacterially 
purified; Mol wt. 40kDa) was used as a positive control while the pRK5 empty 
vector transfected cells were used as control for JNK immunoprecipitation 
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(figure 10B; lane 1). Thus, the in-vitro kinase assay using wild type HA-JNK1 
and kinase dead HA-JNK indicates that C/EBPα is a substrate of JNK1. 
 
3.6 Phosphopeptide analysis of immunoprecipitated C/EBPα from 
transiently cotransfected 293T with MKK7 confirms presence of one 
phosphopeptide:  
To identify the putative phosphopetides and localize the amino acid residue of 
C/EBPα targeted by JNK1, mass spectrometry analysis was done. C/EBPα from 
transiently transfected 293T and cotransfected together with MKK7 was 
immunoprecipitated and separated on 8% SDS PAGE. Further, the gel was 
colloidal Coomassie stained to visualise the C/EBPα band. The 42kD band 
corresponding to C/EBPα from lane 2 and 3 (figure 11A) was carefully excised 
and trypsin digested. After phosphopeptide enrichment, mass spectrometry 
analysis shows the presence of one phosphopeptide corresponding to a spectral 
peak at 1546.74 (1466.74Da+ ~80Da Phosphate group) in tryptic peptides of 
C/EBPα from cotransfection of MKK7 and C/EBPα (figure 11B, middle panel), 
whereas in the control tryptic peptides (figure 11B, upper panel, C/EBPα 
transfected alone) a spectral peak for the non phosphorylated peptide was 
observed.  
 In many cases, the final fraction of phosphorylated molecules is lower 
than 10%, and the percentage is usually even lower when the material stems 
from in-vivo phosphorylation (James, 2001). Thus, we can not rule out the 
possibility of more than one phosphopetide. Alkaline phosphatase (an enzyme 
which removes phosphate groups) treatment of phosphopetides shifts the 
spectral peak 1546.47 to a non-phosphorylated position at 1466.74 (figure 11B, 
bottom panel) which confirms the presence of a phospho peptide. 
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Fig 11. Phosphopeptide analysis of phosphorylated C/EBPα: A) Whole cell lysates from 
293T transiently transfected with C/EBPα alone and together with MKK7 separated on 1D 
SDS PAGE, gel was Coomassie stained and C/EBPα band was excised for mass 
spectrometric analysis. B) After trypsin digestion and phosphopeptide enrichment, one 
phosphopeptide corresponding to C/EBPα tryptic peptide spanning from amino acid 277-286, 
having spectral peak at mass 1547Da (1466.9 + Additional 80Da corresponding to phospho 
group) was observed from C/EBPα band (middle panel spectra) of C/EBPα and MKK7 
cotransfection, while in control (C/EBPα alone transfected; upper panel spectra) this spectral 
peak is seen at unmodified tryptic peptide at mass 1466.9. This was confirmed by alkaline 
phosphatase treatment (lower panel) which removes phospho group and hence peak at 1547 
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shifted back to original position at 1466.79. C) Amino acid sequence of identified 
phosphopeptide.  
 
The spectral peak at 1466.74 corresponds to peptide (K)SVDKNSNEYRVR(R) 
which starts from amino acid 277 and ends at 288. This region contains two 
serine residues though they are not conventional MAPK sites for 
phosphorylation. However, there might be more than one amino acid residue 
getting phospho modified. 
Since this region is also present in GST-DBD, we next asked if JNK1 can 
phosphorylate GST-DBD. An in-vitro kinase assay using GST-DBD as substrate 
and immunoprecipitated HA-JNK and HA-JNK* (kinase dead JNK mutant)  
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Fig 11. D) JNK1 phosphorylates GST-DBD in an in-vitro kinase assay : In-vitro kinase 
reaction using GST-DBD, GST-c-Jun as substrate and immunoprecipitated HA-JNK1 and 
HA-JNK1* from the transiently transfected 293T together with its activator MEKK1 as 
kinase shows that GST-DBD could be phosphorylated (lane 4) while much less with HA-
JNK1* (lane 5) in autoradiogram (upper panel). Same membrane was stripped and blotted 
with anti GST to show presence of substrate, GST-c-Jun (GST fused with 1-79 amino acids of 
c-Jun; cell signalling technology, Germany) has size of 35 kDa.  
 
respectively as kinase from transiently cotransfected 293T together with 
MEEK1 shows that GST-DBD can be phosphorylated by wild type JNK while 
there is little or no phosphorylation with mutant HA-JNK. GST-c-Jun was used 
as control (figure 11D).  
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3.7 JNK targets ubiquitination of C/EBPα: 
JNK is known to regulate ubiquitination and hence protein stability of its 
physically associated substrates (Fuchs et al., 1997). Besides, C/EBPα is also 
known to be regulated by ubiquitination (Subramanian et al., 2003). Hence, we 
asked whether JNK can also target C/EBPα ubiquitination. We performed an in- 
vivo ubiquitination assay by transiently transfecting 293T cells with HA tagged 
ubiquitin (HA-Ubi) alone, together with C/EBPα, and MKK7 respectively.  24h 
post transfection cells were harvested and a whole extract was prepared.    
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Fig 12. A) Inactive JNK targets C/EBPα ubiquitination: In-vivo HA-ubiquitination assay 
was performed by transfecting 293T cells with the expression plasmids for HA-Ubiquitin, 
hC/EBPα, and MKK7 as indicated, 24 post transfection cells were lysed and C/EBPα was 
immunoprecipitated. Immunoblot against HA antibody shows that C/EBPα is heavily 
ubiquitinated (lane 4), while this ubiquitination was inhibited upon JNK activation by co-
transfection of MKK7 (upper panel). Membrane was stripped and reprobed for C/EBPα 
(lower panel) as control for C/EBPα immunoprecipitation. 
 
An immunoblot against anti HA after immunoprecipitation of C/EBPα shows 
that C/EBPα is highly ubiquitinated when co-transfected with HA-Ubi (figure 
12A, lane 4). However this ubiquitination was inhibited in HA-Ubi, C/EBPα 
and MKK7 co-transfected cells where JNK1 was activated by MKK7 (figure 
12A, lane 5); MKK7 is known to directly interact and activate JNK1 (Moriguchi 
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et al., 1997). Owing to the fact that C/EBPα is overexpressed in this experiment, 
the steady state C/EBPα protein level in lane 5 does not seem to change upon 
inhibition of ubiquitination. However, the increase in the steady state 
C/EBPα protein level is expected after extended time points. Activation of 
JNK1 upon induction with a low amount of TNFα (20ng) also resulted in 
inhibition of C/EBPα ubiquitination, though it was not as efficient as with 
MKK7 induced JNK activation (data not shown). To our knowledge this is first 
report of the modulation of C/EBPα ubiquitination by JNK1. 
 
3.8 Anisomycin induced activation of JNK1 enhances C/EBPα protein half 
life as compared to uninduced cells in pulse chase labelling assay: Next we 
asked when active JNK1 can inhibit C/EBPα ubiquitination; it should enhance 
the C/EBPα protein half life in a pulse chase assay. For this, HL 60 cells were 
grown in RPMI medium (lacking methionine) supplemented with                     
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Fig 12. B) Anisomycin induced JNK activation prolongs C/EBPα half life: Myelo-
monocytic HL 60 cells were labelled with [35S]-methionine and chased with the cold 
methionine for 0-6h with or without anisomycin treatment, as described in materials and 
methods. C/EBPα was immunoprecipitated from equal amount of protein (250µg), and 
analysed by autoradiography after separating on 10% SDS PAGE. Result of pulse chase was 
quantified using phosphor imager with AIDA software (Raytest, Germany), depicted in graph, 
which represents values with error of <15%).  
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[35S] - methionine and dialysed FBS for 10 minutes with continuous shaking at 
37°C in a water bath, and then chased in normal medium (RPMI with 
methionine and non dialysed FBS) for different time points as indicated (figure 
12B). Cells were harvested after indicated time points and C/EBPα was 
immunoprecipitated. The autoradiogram developed after 2 days shows that 
C/EBPα half life is prolonged when induced with anisomycin as compared to 
uninduced cells. 
 
3.9 Induced activation of JNK enhances C/EBPα protein expression in 
Western blot analysis: Because active JNK1 inhibits C/EBPα ubiquitination 
and prolongs its half life, we next asked whether activation of JNK1 can 
enhance the C/EBPα protein expression. For this, we induced acute 
promyelocytic NB4 cells with 25ng/ml anisomycin, which is a chemical 
activator of JNK (Bogoyevitch et al., 1995). Cell lysates prepared after different 
time points as indicated were separated on 8% SDS PAGE. The immunoblot 
against C/EBPα shows that C/EBPα protein expression is significantly 
enhanced upon JNK activation (figure 13A i; in-vitro translated C/EBPα -His, 
47kDa used as positive control for C/EBPα). The same lysates were separated in 
a different gel and were immunoblotted against phospho-c-Jun as a measure of 
JNK kinase activity (figure 13Aii) upon anisomycin induction; note that a casual 
relationship between JNK activation and active JNK induced C/EBPα 
expression was established using SP600125 JNK inhibitor (figure 13D). The 
increase in C/EBPα protein expression was consistent with JNK activation. 
Similar effects were observed with U937 (data not shown) and acute 
myelomonocytic HL60 cells, when treated with 25ng/ml of anisomycin (figure 
13B). That induction of HL60 cells with 25ng/ml anisomycin significantly 
activates JNK1 is published elsewhere (Terrance A. Stadheim, 2002). C/EBPα 
protein expression upon JNK1 activation was also investigated in the C/EBPα 
inducible cell line K562Er-C/EBPα, where Er-C/EBPα is activated when 
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induced with 1µM β-estradiol (Cleaves et al., 2004) but with accelerated 
degradation, The immunoblot against C/EBPα shows that anisomycin induction 
together with β-estradiol can reduce the degradation of Er-C/EBPα (figure 13C). 
This strengthens our data that inactive JNK targets C/EBPα for ubiquitination.     
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Fig 13. Anisomycin induced activation of JNK1 enhances C/EBPα protein expression: 
A) i. Immunoblot showing enhanced expression of C/EBPα in NB4 (PML/RAR harbouring) 
cells after induction with 25ng/ml anisomycin. In-vitro C/EBPα-His used as positive control 
(last lane), while lower panel is loading control. ii. Same lysates were separated on different 
gel and probed for phosphor c-Jun to measure anisomycin induced activation of JNK kinase 
activity. Lower panel is loading control probed with β-tubulin. B). HL 60 cells induced with 
25ng/ml  of anisomycin for different time points as indicated were lysed in RIPA buffer and 
separated on 10% SDS PAGE, immunoblot against C/EBPα antibody shows a significant 
increase in C/EBPα protein after 30 min as compared to uninduced cells, lower panel is 
loading control. C) Anisomycin stabilizes C/EBPα in β-estradiol inducible C/EBPα cell 
line K562Er-C/EBPα: Estradiol Receptor fused to C/EBPα stably transfected in K562 cells 
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was treated with 25ng/ml anisomycin for different time points as indicated and whole cell 
lysates were prepared in RIPA buffer. Immunoblot against an anti C/EBPα antibody shows 
the rate of degradation of C/EBPα is slower in anisomycin induced cell lysates as compared 
to cells treated with β-estradiol (Est) alone, lane one is control K562Er empty vector. Lower 
panel is loading control probed with β-Tubulin.  
     
3.10 MEKK1 cotransfection with C/EBPα leads to accumulation of 
C/EBPα: To explore further if JNK1 activation contributes to C/EBPα elevated 
expression, we cotransfected 293T cells with JNK1 and MEKK1. It is well 
established that MEKK1 is an upstream activator of JNK (Fuchs et al., 1997). 
24h post transfection cells were harvested by lysing in RIPA buffer. Equal 
proteins were separated on 8% SDS PAGE. The immunoblot against anti 
C/EBPα antibody shows that MEKK1 significantly enhances the C/EBPα 
protein expression while this effect was abrogated when cotransfected cells were 
treated with 20µM JNK inhibitor SP600125 (Han et al., 2001) 3h post 
transfection (figure 13D). This suggests that JNK1 activation is indeed required 
for stabilization of the C/EBPα protein. To investigate whether JNK affects 
C/EBPα at the protein level and not at mRNA, we treated U937 cells with 
50µg/ml cycloheximide, a potent inhibitor of protein synthesis prior to the 
addition of 50ng/ml anisomycin for different time points as indicated.     
 
            
β−Tubulin
293T +         +      +        +       +     +
hC/EBPα - +       - +       +     -
MEKK1 - - +        +       +     -
SP600125 - - - - +     +
C/EBPα
→
→
D.
CHX                   CHX+Ani
h        0      0.5     1    1.5    0     0.5     1     1.5
C/EBPα
β−Tubulin
→
→
E.
 
Fig 13. D) MEKK1 enhances the C/EBPα protein expression: 293T cells were transiently 
transfected with C/EBPα and MEKK1 expression plasmids, 24h post transfection cells were 
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lysed and equal amount of protein was separated on 10% SDS PAGE, Immunoblot against a 
C/EBPα antibody shows a significant increase in C/EBPα (lane 4) while, MEKK1 induced 
increase in C/EBPα protein was drastically decreased when cells were treated with 20µM 
JNK inhibitor SP600125, lower panel is loading control immunoblotted with β-tubulin. E) 
Anisomycin induced activation of JNK affects C/EBPα at the protein level: U937 cells 
were treated with cycloheximide (CHX) prior to treatment with anisomycin as described in 
materials and methods. A whole cell extract was separated on 10% SDS PAGE and 
immunoblotted against a C/EBPα (upper panel) antibody, Immunoblot against β- tubulin 
(lower panel) is loading control for equal amount of protein.  
 
The immunoblot against C/EBPα after separating whole cell extracts on 8% 
SDS PAGE shows that C/EBPα protein degradation is reduced when treated 
together with anisomycin (figure 13E). The increase in protein amount after 0h 
may be attributed to JNK activation by cycloheximide itself (Kyriakis and 
Avruch, 1990). 
 
3.11 Active JNK1 enhances the ability of C/EBPα to transactivate the 
minimal TK promoter driven by C/EBP DNA binding sites p(C/EBP) 2TK:   
To ascertain if the active JNK induced increase in C/EBPα protein expression is 
also accompanied by an increase in C/EBPα transactivation activity, we 
transfected 293T cells with a minimal TK promoter containing 2C/EBP sites 
cloned upstream of the luciferase reporter gene along with expression plasmids 
for hC/EBPα (human C/EBPα) and MEKK1. The reporter gene expression of 
the luciferase reporter gene was determined 24h post transfection. Transfection 
of the MEKK1 expression construct significantly enhanced the ability of 
C/EBPα to transactivate the minimal C/EBP promoter upto 5fold, whereas this 
effect was drastically reduced to 1.5fold when C/EBPα and MEKK1 
cotransfected cells were treated with a JNK inhibitor 3h post transfection. No 
significant change was observed in the pTK luc empty vector (figure 14). This 
confirms that the active JNK1 induced increase in C/EBPα protein level 
contributes to C/EBPα transactivation activity. 
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Fig 14. JNK1 enhances the C/EBPα transactivation capacity: MEKK1 induced activation 
of JNK enhances C/EBPα transactivation capacity; 293T cells were transiently transfected 
with expression plasmids pCDNA3-hC/EBPα, pCDNA3-MEKK1 and a minimal TK 
promoter driven by C/EBP DNA binding sites p(C/EBP)2TK, minimal promoter without any 
C/EBP binding site was used as control. Luciferase activities were determined 24h after 
transient transfection with LipofectAMINE Plus and normalized to the activities of the 
internal control plasmid pRL-null. MEKK1 enhances C/EBPα transactivity almost 5 fold 
while MEKK1 induced increase in C/EBPα transactivation was reduced to 1.5 fold when 
treated with 10µM JNK inhibitor SP600125 (Calbiochem, Germany). There was no major 
change in Luciferase activity in control transfections.  
 
3.12 JNK1 enhances C/EBPα DNA binding activity in Electrophoretic 
Mobility Shift Assay (EMSA): Because JNK1 enhances C/EBPα protein 
expression and its transactivation activity we next asked, if JNK1 also increases 
the DNA binding capacity of C/EBPα. To investigate this, 293T cells were 
transfected with expression plasmids of hC/EBPα, JNK1 and MEKK1 as 
indicated (figure 15). A nuclear extract was prepared 24h post transfection and 
5µg of nuclear extract was used in an EMSA reaction together with a labelled 
probe which is a 30 nucleotide oligomer corresponding to the C/EBPα binding 
region on the G-CSF receptor promoter (Behre et al., 2002b). A significant 
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increase in C/EBPα DNA binding with the probe was observed when the 
nuclear extract from cotransfection of JNK1, C/EBPα and MEKK1 (lane 10) 
was used as compared to a nuclear extract from C/EBPα transfected alone (lane 
2). A supershift with a C/EBPα (lane 4,8 and 12) antibody was observed while 
no binding occurred when a 50-fold excess of the unlabelled probe was used as 
competitor (lane 3,5,7,9,11 and 13). However, antibody supershift like band 
seen in lane 6 and 10 could be unresolved protein-probe complex as this band is 
not seen in lane 2 while equal amount of protein was loaded in each well. These 
results indicate that binding of C/EBPα to the G-CSF receptor promoter DNA is 
enhanced upon C/EBPα stabilization by activated JNK1. 
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Fig 15. JNK1 enhances C/EBPα DNA binding activity in Electrophoretic Mobility Shift 
Assay (EMSA): EMSA analysis using 5µg of nuclear extract from 293T co-transfection of 
JNK1, C/EBPα (lane 6); JNK1, C/EBPα, MEKK1 (lane 10); and C/EBPα alone (lane 2); 
together with radiolabelled probe shows JNK1 enhances (S) C/EBPα DNA Binding Activity. 
Super shifted (SS) complexes are indicated with arrow (lane 4, 8 and 12), for competition 
analysis, a 50-fold molar excess of unlabelled oligonucleotide probe was used (lane 3,5,7,9, 
11 and 13).  
 
3.13 JNK1 mRNA expression is downregulated in AML subtypes: 
Affymetrics analysis of JNK1 mRNA expression from different AML subtypes 
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shows that JNK1 mRNA expression is downregulated in these patients in 
comparison with normal bone marrow mononuclear cells from healthy 
volunteers (figure 16). The affymetrix data for these AML patients has been 
previously reported (Schoch et al., 2002). Standard Affymetrics software (Micro 
array Suite, Version 5.0) and the HG-U133A set of normalization controls were 
used for data analysis. As recommended by the manufacturer, 100 human 
maintenance genes served as a tool to normalize and scale the data prior to 
performing data comparisons. Expression signal intensities are given as absolute 
numbers. AML patient samples included FAB M2 patients with a translocation 
t(8;21), normal karyotypes (NK), complex karyotype (CK), M3 with t(15;17), 
M4eo inversion 16 (inv 16), and MLL. 
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Fig 16. JNK1 mRNA expression is downregulated in AML subtypes: JNK1 mRNA 
expression is decreased in AML patient samples (n = 225) in comparison with normal bone 
marrow (nBM) mononuclear cells (n = 9). Total RNA was isolated and processed as 
described before (Schoch et al. 2002). Expression signal intensities are given as absolute 
numbers (Schoch et al. 2002). The error bars indicate the s.e.m., n indicates the number of 
patient samples analysed in each subgroup. AML patient samples included FAB M2 patients 
with translocation t(8;21), normal karyotype, complex karyotype, M3 with t(15;17), M4eo 
inversion 16, t(11q23), AML complex karyotype, and AML normal karyotype.  
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3.14 Phospho JNK1 expression and its kinase activity is reduced in AML 
subtypes: Because JNK1 mRNA expression is downregulated in AML subtypes 
we next analysed the JNK1 kinase activity from different AML patients. We 
assessed the phospho JNK1 protein expression which served as measure of 
JNK1 kinase activity. Patient samples were lysed in RIPA buffer and 50µg of 
protein from each sample was separated on 8% SDS PAGE. The immunoblot 
developed after blotting against an anti-phospho JNK1 antibody (Cell Signalling 
Technology, Germany) shows that phospho-JNK1 expression (figure17; upper 
panel) is slightly lower as compared to normal bone marrow except for CML 
patients where JNK is reported to be constitutively active. Further we analysed 
the phospho c-Jun expression (figure17; middle panel) by stripping and 
reblotting the same membrane, which is also consistent with a decreased JNK1 
kinase activity in these patients. In AML-FAB subtypes (French-American-
British nomenclature) M2 with t(8;21) and M3 with t(15;17) translocation, 
C/EBPα function is known to be inactive which is due to its inhibition by fusion 
proteins. However, in many cases the reason behind the inactivation of C/EBPα 
is not clear. Here we propose that the downregulation and inactivation of the 
JNK kinase activity may possibly lead to C/EBPα inactivation.  
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Fig 17. JNK kinase activity is decreased in the various AML subtypes: Phospho JNK1 
expression is downregulated in the AML subtypes; Patients samples from different AML 
subtypes M2 t(8,21); M3 t(15,17); M1 and CML were lysed in RIPA lysis buffer. An equal 
amount of protein was separated on 10% SDS PAGE. Immunoblot against an anti phospho 
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JNK1 antibody shows lower phospho JNK1 expression in AML as compared to normal bone 
marrow. Subsequently the same membrane was stripped and blotted for phospho c-Jun which 
is also consistent with lower JNK1 kinase activity except for CML patients where JNK1 is 
reported to be constitutively active (middle panel), lower panel is loading control β−tubulin. 
293T transfected with c-Jun, MKK7 and MEKK1 was used as positive control.  
 
4. Discussion: 
Protein-protein interactions are operative at every biological step and are 
important to the formation of complexes and signal transduction through protein 
pathways. Perturbation in such multi protein complexes often leads to improper 
functioning as seen in diseased conditions (Figeys, 2003). Recent studies have 
emphasized that the interaction of transcription factors with other nuclear 
proteins plays an important role in a combinatorial fashion in stem cell 
development, lineage commitment, differentiation in the haematopoietic system, 
and the pathogenesis of myeloid leukemia (Behre et al., 2002a; Nerlov, 2000). 
Inactivation of key lineage specific factors by mutations has previously been 
shown by us and others. In many cases inactivation of such factors in acute 
myeloid leukemia is not well defined. Direct antagonist protein-protein 
interaction of transcription factors and other regulatory molecules is a newly 
detected mechanism in the pathogenesis of leukemia (Nerlov, 2000; Rangatia et 
al., 2003; Reddy et al., 2002; Tenen, 2000). The inhibition of AML1, C/EBPα 
and PU.1 by direct protein-protein interactions has been implicated in AML. 
C/EBPα being a regulatory switch that is sufficient for the induction of 
granulocytic development from bipotential myeloid progenitors is often 
impaired in AML (Pabst et al., 2001a; Pabst et al., 2001b; Radomska et al., 
1998) either by mutation or inhibition by other proteins (Rangatia et al., 2003). 
Negative protein-protein interactions are not only responsible for the 
inactivation of C/EBPα function in AML, but even C/EBPα itself seems to 
function via protein-protein interactions (Schaufele et al., 2001). Proteomics-
based approaches, which enable the quantitative investigation of both cellular 
protein expression levels and protein-protein interactions involved in signalling 
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networks, promise to define the molecules controlling the processes involved in 
cancer (Simpson RJ, 2001). This prompted us to hypothesize that identifying 
C/EBPα interacting proteins might help in understanding the molecular 
mechanisms underlying leukemogenesis.  
Identification of C/EBPα interacting proteins: High-throughput proteomics 
by mass spectrometric analysis of gel-separated proteins can identify multi-
protein complexes and changes in the expression of multiple proteins 
simultaneously (Behre et al., 2002a). Due to its high throughput, MS-based 
proteomics has been extensively applied for probing molecular mechanisms in 
signal transduction, identifying cancer biomarkers and profiling various diseases 
(Wang et al., 2004). We performed affinity based C/EBPα multiprotein 
purification followed by subsequent MALDI TOF and / or TOF TOF mass 
spectrometric analysis to identify the gel separated proteins. We identified 
unknown as well as few known interacting proteins of C/EBPα such as 
retinoblastoma and SWI/SNF2 though with a low significance score. Here, we 
identified JNK1, a member of the MAP kinase family of proteins with a 
significant mowse score as an interacting protein of C/EBPα. Earlier studies 
have shown that JNK physically interacts with its associated substrates such as 
c-Jun, c-Myc, ATF2. Therefore, we validated the identified spot by western 
blotting and confirmed the physical interaction between JNK1 and C/EBPα in-
vitro (figure 8) and in-vivo (figure 9) respectively. JNK1 and C/EBPα 
interaction was observed with various C/EBP basic region and leucine zipper 
mutants (figure 9B) in co-immunoprecipitation studies. This could be due to an 
intact phosphopeptide region in these mutants.  
Biological implication of the JNK1 and C/EBPα interaction: Previous 
analyses have shown that Ras signalling enhances C/EBPα activity by 
phosphorylating at S248 (Behre et al., 2002b). Recently, C/EBPα has been 
reported to be regulated by post translational modifications such as 
phosphorylation, SUMOylation and ubiquitination (Ross et al., 1999; Ross et al., 
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2004; Subramanian et al., 2003). In this report, we show that JNK1 
phosphorylates C/EBPα in its DNA binding domain (DBD) while the JNK 
mutant (kinase domain dead) could not phosphorylate it (figure 10B). 
Furthermore, by mass spectrometric analysis we identified one phosphopetide 
[(K)SVDKNSNEYRVR (R) which starts from amino acid 277 and ends at 288)] 
corresponding to the BR-LZ region in DBD from tryptic peptides of 
phosphorylated C/EBPα (figure 11B). Still we can not rule out the possibility of 
more than one phosphopetide. There are two serine residues in the identified 
phosphopetide which could be phospho modified though they are not 
conventional S/TP MAP kinase phosphorylation sites; however, they could be 
phosphomodified by MAP kinases (S.Corbalan-Garcia, 1996). We constructed 
two point mutants S277-A (serine 277 mutated to alanine) and S282-A (serine 
282 mutated to alanine) and performed in-vitro kinase assay where we observed 
some altered phosphorylation of these mutants (data not shown). Mutation of 
serine 282 to alanine had not much effect on C/EBPα phosphorylation while 
serine 277 to alanine surprisingly showed an increase in phosphorylation. 
Enhanced phosphorylation of the S277A mutant may be due to a conformational 
change and better accessibility of C/EBPα to JNK1. Thus our data indicate that 
C/EBPα is a substrate for JNK and probably more than one amino acid of 
C/EBPα is being targeted upon the JNK activation. However, extensive study is 
required to identify the amino acid residues being phospho modified.  
In addition to its function as a transcription factor, C/EBPα has been 
reported to act as tumour suppressor gene which inhibits cell proliferation via a 
transcription-independent mechanism in which C/EBPα forms a complex with 
cdk2 and cdk4 preventing cyclin/cdk complex formation, E2F inhibition and cell 
cycle progression. The regulation of the C/EBPα protein level through an 
ubiquitin-proteasomal pathway would control both the transcription-dependent 
and transcription-independent activities of C/EBPα (Shim and Smart, 2003). 
C/EBP proteins and C/EBPα in particular have been reported to be regulated 
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both at mRNA (Perrotti et al., 2002; Timchenko et al., 2002) and protein levels 
(Smart, 2003). Recent findings suggest that the stabilization of the C/EBPα 
protein contributes to its transactivation and growth arrest activity (Wu et al., 
2003a; Wu et al., 2003b); (Yoon and Smart, 2004). Wu et al. show that physical 
interaction between C/EBPα and the Epstein-Barr virus lytic-cycle 
transactivator protein ZTA prolongs C/EBPα and p21 protein levels through 
both transcriptional and posttranslational mechanisms and leads to growth arrest 
in kaposi´s sarcoma cells (Wu et al., 2003a).  
The stress responsive kinase JNK has been shown to regulate the 
ubiquitination dependent degradation of a different subset of substrates by 
acquiring a specific phosphorylation pattern that affects conformation, stability, 
subcellular localization and transcriptional activation (Fuchs et al., 1998d; Musti 
et al., 1997; Ronai, 2004). In non-stressed cells i.e., inactive JNK functions as a 
targeting molecule for ubiquitination, an activity which depends not on the fact 
that it is a kinase, but its ability to associate tightly with its substrate. This 
association attracts the enzymes of the ubiquitination machinery to the substrate, 
thereby marking it for the proteasome-dependent degradation. However, in 
stressed cells i.e. when JNK1 is active, ubiquitination is inhibited (Fuchs et al., 
1998d; Fuchs et al., 1997). The interaction of inactive JNK with c-Jun targets its 
ubiquitination which is inhibited upon phosphorylation of c-Jun by JNK. 
However, it is noteworthy that physical association of JNK with its substrates is 
the only prerequisite for targeting ubiquitination; this is evidenced by the fact 
that Elk1, which is not capable of associating with JNK, can not be targeted for 
ubiquitination and moreover its phosphorylation by JNK does not prevent its 
ubiquitination (Gupta et al., 1995).  Our data is consistent with the above 
findings. Here we report that the physical association between JNK1 and 
C/EBPα, targets ubiquitination of C/EBPα (figure 12A); which is inhibited upon 
activation of JNK by MKK7 in an in-vivo HA-Ubiquitination assay (figure 
12A). We also show in a pulse chase labelling assay that activation of JNK 
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enhances half life of C/EBPα protein which shows that the activation of JNK is 
indeed required for the inhibition of JNK targeted C/EBPα ubiquitination.  
The inhibition of ubiquitination of its associated substrates by JNK 
prolongs their half life and hence expression (Fuchs et al., 1997). Our result is in 
accordance with these findings. We also show that the anisomycin induced 
activation of JNK1 in various leukemic cell lines significantly enhances 
C/EBPα protein expression (figure 13). Further, we show that JNK1 affects the 
C/EBPα protein level rather than its mRNA via an immunoblot against C/EBPα  
from cells lysates of U937 after treatment with cycloheximide alone and 
together with anisomycin (figure 13E). An increase in C/EBPα protein 
expression was consistent with the increase in its transactivation and DNA 
binding activity (figure 14 and 15) which suggests that the regulation of 
C/EBPα protein stability has an impact on its activity. More recently, Yoon K et 
al. have shown that C/EBPα is a DNA damage-inducible p53-regulated 
mediator of the G1 checkpoint in keratinocytes. Their study shows that UVB 
irradiation of keratinocytes enhances the C/EBPα protein expression by 70 fold 
which is accompanied by an upregulation of p53 and p21 expression leading to a 
G1 phase of cell cycle growth arrest. However, UVB (Ultra Violet Radiation B) 
is a potent inducer of the JNK kinase activity which strengthens our data that the 
physical association of active JNK with C/EBPα inhibits its ubiquitination and 
stabilizes it (Yoon K et al., 2004).  
An affymetrics analysis of JNK mRNA from different AML subtypes 
shows that JNK1 mRNA expression in various AML subtypes M2 with t(8;21), 
M3 t(15;17), and inversion 16 is lower in comparison with normal bone marrow 
mononuclear cells from healthy volunteers, Further we show that not only JNK1  
mRNA expression but also phospho JNK kinase expression (which- served as a 
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Fig 18. Model: Functional relevance of JNK1 physical interaction with C/EBPα: On the 
basis of our data we propose a hypothetical model where interaction of active JNK1 with 
C/EBPα prolongs half life of C/EBPα by inhibiting its ubiquitination. JNK induced increase 
in C/EBPα protein results in transcriptional activation. In a symmetrical manner interaction of 
inactive JNK with C/EBPα leads to degradation of C/EBPα and hence results in 
transcriptional repression.  
 
measure of kinase activity) is decreased in such patients (figure 17). Moreover, 
the JNK signal transduction pathway has been implicated in many pathological 
conditions (Manning and Davis, 2003), including cancer. This implicates that a 
JNK activity is required for the C/EBPα activation in myeloid cells and that a 
loss of JNK regulated C/EBPα expression may contribute to leukemogenesis. 
          In conclusion, we propose a hypothetical model (figure 18) of the physical 
interaction of active JNK with C/EBPα. JNK targeting of C/EBPα 
ubiquitination requires the tight interaction with C/EBPα; whereas 
phosphorylation of C/EBPα by JNK inhibits its ubiquitination, presumably due 
to an altered conformation of C/EBPα, which is likely to inhibit ubiquitination 
machinery. This results in an increased C/EBPα stability and availability which 
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is reflected by an enhanced DNA binding and transcriptional activation of 
C/EBPα.  
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5. Summary: 
Functional inactivation of the transcription factor CAAT Enhancer Binding 
Protein Alpha (C/EBPα) either by mutation or direct protein-protein interaction 
leads to acute myeloid leukemia (AML), whereas the activation of C/EBPα 
restores normal myeloid cell differentiation. We and others have shown that 
protein-protein interactions of C/EBPα play a pivotal role in myeloid 
differentiation and AML. In the present study we applied proteomics based mass 
spectrometry to identify C/EBPα interacting proteins on a proteome-wide scale. 
For this, the GST and GST-DNA binding domain of C/EBP (GST-DBD) was 
incubated with nuclear extracts of U937 cells. Interacting proteins separated by 
two-dimensional gel electrophoresis were identified by MALDI-TOF mass 
spectrometry. Using this approach we could identify PAK6, MADP-1, ZNF45 
and the c-Jun N-terminal kinase 1 (JNK1) as C/EBPα interacting proteins. Since 
JNK1 activates c-Jun, the contra-player for C/EBPα, we hypothesized that the 
JNK1 and C/EBPα interaction might have some biological relevance. We could 
show that JNK1 binds to the DNA binding domain of C/EBP in GST-pull-down 
and to the C/EBPα in co-immunoprecipitation assays in-vitro and in-vivo 
respectively. JNK1 phosphorylates and increases the half life of the C/EBPα 
protein via inhibiting its ubiquitination and thereby enhances its transactivation 
and DNA binding activity. Furthermore, JNK mRNA expression as well as its 
kinase activity is lower in the AML patients in comparison to normal bone 
marrow mononuclear cells which implicates a possible mechanism of C/EBPα 
inactivation in certain acute myeloid leukemia subtypes. Thus our data suggest 
that a JNK activity is required for C/EBPα activation in myeloid cells and a loss 
of JNK regulated C/EBPα expression may contribute to leukemogenesis.  
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6. ZUSAMMENFASSUNG 
Die funktionelle Inaktivierung des Transkriptionsfaktors CAAT Enhancer 
Binding Protein alpha (C/EBPα) entweder durch Mutation oder durch direkte 
Protein-Protein-Interaktion führt zu akuter myeloischer Leukämie (AML), 
wohingegen die Aktivierung von C/EBPα eine normale myeloische 
Differenzierung gewährleistet. Wir und andere konnten zeigen, dass Protein-
Protein-Interaktionen von C/EBPα eine entscheidende Rolle in der myeloischen 
Differenzierung und AML spielen. In der vorliegenden Studie haben wir die auf 
Proteomik basierende Massenspektrometrie genutzt, um die mit C/EBPα 
interagierenden Proteine in einem Proteom-weiten Maßstab zu identifizieren. Zu 
diesem Zweck wurde ein Fusionsprodukt aus GST und der DNA-bindenden 
Domäne von C/EBPα mit Kernextrakten von U937 inkubiert. Mit C/EBPα 
interagierende Proteine wurden mittels zweidimensionaler Gelelektrophorese 
separiert und durch MALDI-TOF-Massenspektrometrie identifiziert. Mit diesem 
Ansatz konnten wir PAK6, MADP-1, ZNF45 und die c-jun N-terminale Kinase 
1 (JNK1) als interagierende Proteine von C/EBPα identifizieren. JNK1 aktiviert 
c-jun, einen Gegenspieler von C/EBPα. Daher stellten wir die Hypothese auf, 
dass die Interaktion von JNK1 und C/EBPα eine biologische Relevanz haben 
könnte. Wir konnten mittels GST-Pull-Down-Experimenten in-vitro zeigen, dass 
JNK1 mit der DNA-bindenden Domäne von C/EBP interagiert. Die Interaktion 
von JNK1 und C/EBPα konnte in-vivo durch Koimmunopräzipitation bestätigt 
werden. JNK1 phosphoryliert C/EBPα und erhöht dessen Halbwertszeit durch 
die Hemmung der Ubiquitinylierung. Dadurch wird die Stärke der Bindung von 
C/EBPα an die DNA und seine Fähigkeit zur Transaktivierung erhöht. 
Interessanterweise ist die Expression der JNK1-mRNA und die Kinaseaktivität 
von JNK1 bei AML-Patienten verglichen mit den entsprechenden Werten in 
mononukleären Zellen aus dem Knochenmark gesunder Kontrollpersonen 
erniedrigt. Dies weist auf einen möglichen Mechanismus zur funktionellen 
Inaktivierung von C/EBPα in bestimmten Subtypen der AML hin. 
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Zusammengefasst weisen unsere Daten darauf hin, dass die Aktivität von JNK1 
für die Aktivierung von C/EBPα in myeloischen Zellen nötig ist, und dass ein 
Verlust der durch JNK1 regulierten Aktivität von C/EBPα einen möglichen 
Beitrag zur Leukämie-Entstehung leistet.  
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10. Appendix: 
 
Buffers and their Composition: 
 
Blocking Buffer: 5.0% milk in TBST (1X TBST: Tris 12.1g/L, NaCl 17.6g/L, 
0.02% Tween-20)   
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Staining: 0.1% Colloidal Coomassie Blue G-250, 2% H3PO4, 10% Ammonium 
Sulphate and 20% Methanol 
Destaining: 25% Methanol 
 
Coimmunoprecipitation Buffer: 1% TBS, 0.5% NP40 and Protease inhibitors 
 
DHB Matrix Solution:  9:1 ratio of DHB: HMB 
20 mg/ml 2,5-Dihydroxy-Benzoicacid (DHB); (Merck, Germany) 
20 mg/ml 2-Hydroxy-5-Methoxy-Benzoicacid (HMB); (Merck, Germany) 
 
Kinase Buffer: 150mM NaCl, 1mMEDTA, 50mM Tris-HCl, pH 7.5,  
10mM MgCl2, and 10 mM DTT,  
 
Immobilin Strip Equilibration Buffer: 
i) Reducing Buffer/Strip (1M Tris pH 6.8, Urea, 80% Glycerol 20% SDS and 
0.2g DTE) 
ii) Alkylating Buffer (1M Tris pH6.8, Urea, 80% Glycerol 20% SDS and 0.25g 
Iodoacetamide) 
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Laemmli Buffer (SDS loading buffer 2X, 1L): 125mM Tris pH 6.8, 4% SDS, 
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Nuclear Extract Buffer A:  20mM HEPES, 10mM NaCl, 3mM MgCl2, 1% NP-
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Silver staining: 
Fixing: 50% Ethanol, 12%Acetic Acid  
Sensitising: 200mg/L Sodium Thiosulphate (Na2S2O3 5H2O) and 30% Ethanol 
Silver Reaction: 2g/L Silver Nitrate (AgNO3)  
Developing Buffer: 5mg/L Sodium Thiosulphate (Na2S2O3 5H2O), 60g/L 
Sodium Carbonate (Na2CO3) and 500µl Formaldehyde 37% (HCHO) 
Stopping: 14.60g/L Sodium-EDTA 
 
Transfer Buffer (1x, 1L): 3g Tris base, 14.1g Glycine, 200ml Methanol and 
dH2O  
 
Urea Lysis Buffer: 9.8M Urea, 1% DTE, 4% CHAPS, 2.5mM EDTA and   
2.5mM EGTA 
 
Washing Buffer: 2.5% milk in TBST 
 
 
 
 
       
 
 
 
